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Abbreviations 
AD Alzheimer`s disease 
CSF Cerebrospinal fluid 
ELISA Enzyme-Linked ImmunoSorbent Assay 
[18F]-FDG-PET 18F-Fluoro-desoxyglucose-PET 
FEF Frontal Eye Field 
GD3 Gaucher disease type 3 
INC Nucleus interstitialis Cajal 
MVN Medial vestibular nucleus 
NFT Neurofibrillary tangles 
NP-C  Niemann-Pick disease type C 
NPH Nucleus praepositus hypoglossi 
mDRS modified Disability Rating Scale 
PEF Parietal Eye Field 
PPRF Paramedian pontine reticular formation 
rCGMglc Regional cerebral metabolism for 
glucose 
riMLF Rostral interstitial nucleus of medial 
longitudinal fascicle 
SARA Scale for the Assessement and Rating of 
Ataxia 
SCAFI Spinocerebellar Ataxia Functional Index 
UVL Unilateral vestibular loss 
VC Vestibular compensation 
VSGP Vertical supranuclear gaze palsy 
VSSP Vertical supranuclear saccade palsy 
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Summary 
Niemann-Pick type C (NP-C) is an autosomal recessive lysosomal storage disorder. Symptoms of 
NP-C disease are heterogeneous and include neurologic, psychiatric and systemic manifestations. 
The leading symptom of the disease is cerebellar ataxia, which considerably reduces the quality 
of life and functioning of these patients.  
 There is no causal cure and progressive Purkinje cell degeneration leads to severe ataxia. 
There is a disease-specific therapy with miglustat, a small iminosugar molecule that reversibly 
inhibits glycosphingolipid synthesis, reducing the progression rate of the disease. Thus, 
symptomatic therapies of ataxia are needed to alleviate the burden of the disease and improve the 
quality of life of patients and their caregivers. 
 This dissertation includes two studies that were concerned with the treatment and 
pathophysiology of NP-C disease. The first study evaluates the effects of the modified amino-
acid acetyl-DL-leucine in a cohort of twelve patients with NP-C disease. To quantify their 
response, patients were examined by means of clinical rating scales: the Scale for the 
Assessement and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index 
(SCAFI) and a modified Disability Rating Scale (mDRS). Scales were administered before the 
therapy with acetyl-DL-leucine, after one month of therapy and after one month of washout. 
Subjective improvement was assessed by the EuroQuality of Life questionnaire with visual 
analog scale (EQ-5D-5L). This first study found that with acetyl-DL-leucine therapy, clinical 
scales SARA and mDRS, as well as subtests of the SCAFI (i.e. 8-Meters walking time and 9-
Hole pegboard test of the dominant and non-dominant hand) significantly improved. Moreover, 
family members described an increase of patients` independent daily activities, as well as a 
diminishing of the intensity of square wave jerks. The conclusion of the first study was therefore 
that administration of acetyl-DL-leucine reduces cerebellar symptoms in patients with NP-C 
disease.  
 As postural imbalance is also a well-known feature of NP-C disease, the second 
aforementioned study evaluated whether an impairment of the vestibular system (canal and 
otolith function) contributes to the impairment of stance and gait in patients with NP-C disease. 
Patients were examined by means of the video-head impulse test to evaluate the angular 
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horizontal vestibulo-ocular reflex, cervical and ocular vestibular evoked myogenic potentials for 
otolith function and posturography.  
 The second study found that, contrary to other inherited metabolic disorders, such as 
Gaucher disease, vestibular function is intact in NP-C disease, implying that postural imbalance 
is of cerebellar origin, as was also shown by frequency analyses of posturographic data.  
 All in all, these two studies improve our knowledge of the treatment and pathophysiology 
of NP-C disease. 
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Introduction 
1.1 Niemann-Pick type C disease 
Niemann-Pick type C (NP-C, ORPHA no. 646) is a progressive, autosomal recessive, lysosomal 
storage disorder with a prevalence of 1:100.000 (Orphanet: Reports, 2015). Over 200 different 
mutations have been identified in NPC1 (95% of cases) or NPC2 (≈ 4% of cases) genes for 
proteins important in intracellular trafficking and transport of cholesterol and glycolipids (Alavi 
et al., 2013; Carstea et al., 1997; Fusco et al., 2012; Maue et al., 2012; Naureckiene et al., 2000; 
Park et al., 2003; Steinberg et al., 1994). Defects result in a cellular accumulation of endocytosed 
unesterified cholesterol, sphingomyelin (Butler et al., 1993), glycosphingolipids and sphingosine 
(te Vruchte et al., 2004) in the late endosome/lysosome, leading to functional disturbance of 
neural and non-neural tissues (Vanier and Millat, 2003). Based on the age of the first 
manifestation, the disease can be divided into early-infantile (< 2 years), late-infantile (2 to < 6 
years), juvenile (6 to < 15 years), and adolescent/adult (≥ 15 years) forms (see Figure 1). A 
primary characteristic of NP-C disease is its phenotypic heterogenity, comprising systemic, 
neurologic and psychiatric signs, that are not disease specific, arise at different ages, and progress 
at different rates (Garver et al., 2007; Iturriaga et al., 2006; Patterson et al., 2013; Vanier, 2010).  
                       
Figure 1. Schematic depiction of the clinical findings in Niemann-Pick type C disease. 
Adapted from (Vanier, 2015), with permission.  
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 The diagnosis is established based on the filipin staining of cultured skin fibroblasts, 
showing pathological cholesterol storage and subsequently confirmed by molecular mutation 
analysis of the NPC1 and NPC2 genes (see Figure 2) (Patterson et al., 2012). Moreover, 
oxysterole plasma levels (Porter et al., 2010), targeted new-generation sequencing technologies 
(McKay et al., 2014) and plasma lysosphingomyelin levels (Welford et al., 2014) are promising 
biomarkers both for diagnosing and monitoring treatment response, respectively.  
 
 
Figure 2. Accumulation of unesterified cholesterol visualized by filipin staining and 
fluorescence microscopy in skin fibroblasts cultured in presence of low-density lipoprotein. 
(a) Classic Niemann–Pick type C (NP-C) cell line; (b) variant NP-C cell line; (c) normal cell line. 
Adapted from (Vanier and Millat, 2003), with permission.  
 
1.1.1 Neurological manifestations and their neuropathological, morphological and 
functional correlates 
The most common neurologic finding in patients with NP-C disease is cerebellar ataxia 
(Patterson et al., 2013). Clinically, patients feature stance and gait ataxia with subsequent falls, 
clumsiness, dysmetria and dysdiadochokinesia. The ataxia in NP-C disease results from 
progressive Purkinje cell loss. Purkinje cells are the only neurones projecting out of the cerebellar 
cortex (Sarna et al., 2003). This is accompanied by microglial activation and monocyte 
recruitment to the brain. 
 Tremor is also a common finding, being mainly of cerebellar origin, but having also 
dystonic, myoclonic and choreiform components (Floyd et al., 2007). Remaining neurologic 
manifestations feature dystonia, dysarthria (caused by both cerebellar and cranial nerve 
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involvement), dysphagia, cognitive impairment, seizures, myoclonus and gelastic cataplexy 
(Patterson et al., 2013, 2015). These clinical symptoms indicate a progressive neurodegeneration.  
On the cell level, ballooned neurons distended due to lipid storage, axonal spheroid 
formation, ectopic dendritogenesis, and demyelination can be seen (Bu et al., 2002; Sturley et al., 
2004; Walkley and Suzuki, 2004). Moreover, neurofibrillary tangles (NFTs) (Suzuki et al., 
1995), strongly reacting to antibody to tau-protein (Love et al., 1995), similar to those found in 
Alzheimer`s disease (AD) has been found. In NP-C, however, the tau-protein is predominantly 
distributed in subcortical structures, such as basal ganglia, thalami and hypothalami. Thus, both 
NP-C and AD can be classified as tauopathies (Williams, 2006), as in both, an increased CSF T-
tau level can be found (Mattsson et al., 2011).  
 Neuroimaging studies also demonstrated a neurodegeneration in NP-C. Prior imaging 
studies showed grey matter reductions in subcortical and cortical areas, leading to general 
cerebral atrophy and thinning of the corpus callosum in NP-C disease (Walterfang et al., 2011; 
Walterfang et al., 2013). An increased signal in periatrial white matter, reflecting secondary 
demyelination, is also a common finding (Huang et al., 2011). Also, an atrophy of the cerebellar 
vermis has been described in severe cases of NP-C disease (Fusco et al., 2012). 
The loss of the cerebellar grey matter tracks with disease severity and horizontal saccadic 
function, which is a measure of the functional integrity of brainstem and its efferents, inclusive 
cerebellar vermis (Bowman et al., 2015). Reduced saccadic gain has been previously correlated 
with the loss of cerebellar volume (Walterfang et al., 2013).  
 
1.1.1.1 Cerebellar involvement, assessed by posturography 
To maintain postural balance, the intact functions of the cerebellum, vestibular system and 
proprioception are needed (Brandt et al., 2012). In clinical practice, posturography can be 
administered to assess these balance components (Krafczyk et al., 2006). In addition, a precise 
topo-anatomical diagnosis can be created based on the evaluation of the presence and direction of 
the sway and visual stabilisation in conditions with eyes open/closed (Romberg quotient, RQ) 
(Diener et al., 1984) (see Table 1).  
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Table 1. Flow diagram for the topo-anatomical diagnosis of ataxia of stance. Adapted from 
(Diener et al., 1984), with permission. Abbreviations: RQ Romberg quotient AP antero-posterior 
LAT lateral  
 
1.1.2 Ocular motor manifestations 
Vertical supranuclear saccade palsy (VSSP) represents a cardinal symptom of NP-C disease at all 
disease stages, often being the initial sign of the disease. This finding was observed in 70% of 
patients from an international disease registry (Patterson et al., 2013) and in 81% of patients, 
found in a large-scale observational study (Garver et al., 2007). The saccadic dynamics in the 
course of NP-C disease has provided a measure of the therapeutic effect of miglustat, called 
horizontal saccadic eye movement (HSEM)-α, which is a slope of the linear regression line of 
peak duration vs. amplitude, identifying it as a treatment for this disorder (Patterson et al., 2007). 
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Vertical eye movements are affected much earlier in the course of disease than horizontal 
ones (Abel et al., 2012; Rottach et al., 1997). This is due to the selective functional impairment 
of vertical burst neurons leading to neuronal loss in the rostral interstitial nucleus of medial 
longitudinal fascicle (riMLF). In contrast, horizontal saccades seem not to be impaired because 
premotor burst neurons in the paramedian pontine reticular formation (PPRF), the interstitial 
nucleus of Cajal (INC) and ocular motoneurons remain intact (for anatomical depiction, see 
Figure 3). This was demonstrated in a histopathological examination of the brain of a patient with 
NP-C disease (Solomon et al., 2005).  
 
Figure 3. Depiction of the ocular motor nuclei in a sagittal section of the monkey brainstem. 
The paramedian pontine reticular formation (PPRF) (shaded region in pons), contains premotor 
excitatory burst neurons (EBN) for horizontal saccades (black oval in lower PPRF). The 
medullary reticular formation (Med RF), contains premotor inhibitory burst neurons (IBN) (black 
oval in upper Med RF). The asterisk just caudal to the cranial nerve VI (CN VI) rootlets depicts 
the location of the omnipause neurons in the raphe interpositus. Abbreviations: PC, posterior 
commisure; riMLF, rostral interstitial medial longitudinal fasciculus; INC, interstitial nucleus of 
Cajal; CN III, oculomotor nerve fascicle; III, oculomotor nucleus; IV, trochlear nucleus; MLF, 
medial longitudinal fasciculus; VI, abducens nucleus; CN VI, abducens nerve rootlets; NRTP, 
nucleus reticularis tegmenti pontis. Courtesy of Jean Buttner-Ennever, adapted from (Rucker et 
al., 2011), with permission.  
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Upward, but especially downward saccades are slow, leading to an initial downward 
saccade palsy. Recent monkey and human studies identified a calretinin-positive excitatory input 
to motor centers mediating upgaze, arising from premotor centers: INC, riMLF and y-group (see 
Figure 4) (Che Ngwa et al., 2014; Zeeh et al., 2013, 2015). The lack of this input in downgaze 
pathways might explain the accentuated downgaze deficits in NP-C disease (Adamczyk et al., 
2015). Calretinin is a calcium-binding protein, and in combination with parvalbumin and 
perineuronal nets can contribute to the future identification and subsequent analysis of the upgaze 
vs. downgaze ocular motor disturbances (Adamczyk et al., 2015). 
 
                        
 
Figure 4. Calretinin input is restricted to motoneurons for upward eye movements in the 
monkey. Summary diagram depicting the premotor pathways for upward eye movements (red), 
which are associated with calretinin. Abbreviations: RIMLF, rostral interstitial nucleus of the 
medial longitudinal fascicle; INC, interstitial nucleus of Cajal; CCN, central caudal nucleus; nIII, 
oculomotor nucleus; nIV, trochlear nucleus; LP, levator palpebrae; SO, superior oblique; MR, 
medial rectus; IR, inferior rectus and SR, superior rectus motoneurons. Adapted from (Zeeh et 
al., 2013), with permission. 
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The downward saccadic palsy has also been explained by a bilateral innervation of 
elevator muscles superior rectus and inferior oblique and unilateral (ipsilateral) innervation of the 
depressor muscles inferior rectus and superior oblique (Salsano et al., 2012). Thus, further studies 
are needed to clarify the specific patterns of saccadic degenerations in neurodegenerative 
disorders.  
Up to now, ocular motor systems such as saccades or vestibulo-ocular reflex (VOR) have 
been investigated in a small number of patients (N<9) with NP-C disease (Abel et al., 2012; 
Rottach et al., 1997; Solomon et al., 2005), and as such systematic, exploratory, large-scale 
oculomotor studies in NP-C are still missing. Such studies will help finding reliable ocular motor 
parameters, which could be used as biomarkers in disease progress, and potentially be useful in 
monitoring treatment response. 
 
1.1.3 Psychiatric manifestations  
Psychiatric signs and symptoms often precede the neurologic manifestation (Maubert et al., 
2013). The whole range of psychiatric symptoms include schizophrenic symptoms (paranoid 
delusions, auditory hallucinations, interpretative thoughts, disorganisation), depression, bipolar 
disorder, obsessive-compulsive behavior, behavioral disorders such as hyperactivity, agitation, 
aggressivity, mutilations, and sleep disorders. An underlying NP-C etiology may be suspected 
when patients do not response to psychiatric treatment, or if there is aggravation or confusion 
under the neuroleptic therapy, together with observable catatonia, or seizures (Faludi et al., 2013; 
Maubert et al., 2013; Tyvaert et al., 2005).  
Neurologic symptoms, appearing later on in the course of disease are often explained as 
an adverse event of the antipsychotic medication. The extreme heterogeneous, non-specific 
psychiatric manifestations lead to underdiagnosing of NP-C disease in psychiatric departments, 
leading to a considerable delay of 7 years on average between the initial symptoms and the 
establishing of the diagnose (Patterson et al., 2013).  
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1.1.4 Systemic signs 
The systemic symptoms comprise enlargement of visceral organs, with neonatal jaundice and 
hepatomegaly in early-infantile forms and splenomegaly in juvenile and adult-forms. In older-
onset cases, (hepato-)splenomegaly is usually asymptomatic, but probably present in almost 90% 
of all cases (Sévin et al., 2007). Pulmonary infiltration with foam cells is usually seen in patients 
with early-onset disease (Griese et al., 2010) or those with NPC2 mutations (Bjurulf et al., 2008). 
Systemic involvement, when present, usually precedes neurologic manifestations, suggesting an 
unknown difference in the pathophysiological mechanisms underlying visceral symptoms 
compared to those contributing to neurologic symptoms (Vanier, 2010).  
  
1.1.5 Therapy with miglustat 
The goal of the treatment of NP-C disease is a stabilisation or a reduction in the progression rate 
of neurologic manifestations. The iminosugar miglustat (Zavesca
TM
) is an inhibitor of 
glucosylceramide synthase, that is an enzyme that catalyzes the first committed step in 
glycosphingolipid biosynthesis (Platt et al., 1994).  
 Miglustat slows down the progression rate of the neurologic manifestations in patients 
with NP-C disease. It is the only disease-specific drug approved for the therapy of NP-C disease 
(Patterson et al., 2007). Due to its small molecular weight, miglustat distributes easily after oral 
ingestion, and is able to pass the blood-brain barrier, which is supposed to be a key-factor in the 
treatment of neurologic symptoms. However, the effect of treatment starts with a delay of 6 to 12 
months, and it may be even longer in patients with late-onset disease (Patterson et al., 2012). 
Data from miglustat-treated patients (n = 92) included in the international NP-C registry suggest 
that therapy with miglustat longitudinally stabilizes or improves neurologic manifestations 
(Fecarotta et al., 2015; Patterson et al., 2013). Stabilization of dysphagia is of particular 
importance because it is a high-risk factor for aspiration pneumonia (Walterfang et al., 2012).  
 A longitudinal imaging study comparing patients on miglustat therapy versus untreated 
patients showed that untreated patients with NP-C appeared to loose cerebellar grey and white 
matter, bilateral thalamic volume and right caudate volume faster than miglustat-treated patients 
(Bowman et al., 2015). These changes also correlated with changes in clinical rating scales.  
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 Although miglustat demonstrates a good risk-safety profile (Brand et al., 2015; Hollak et 
al., 2009), gastrointestinal adverse events, such as diarrhea and flatulence are quite common. 
However, this tend to decrease in frequency and intensity over time (Champion et al., 2010). 
 
1.2 Acetyl-DL-leucine 
Acetyl-DL-leucine is an acetylated derivative of the essential amino-acid leucine. It has been 
used for the symptomatic treatment of vertigo and dizziness in France since 1957. Clinical 
experience has shown that it is a well-tolerated and safe drug without serious adverse effects 
(Lacour 1985; Léger et al. 1986; Neuzil et al. 2002; Pierre Fabre Médicaments, Castres, France). 
Acetyl-DL-leucine is able to cross the blood-brain barrier, explaining the reported effects and 
treatment responses in animal models and patients with unilateral vestibular loss (UVL) and 
cerebellar ataxia. 
 The effects of acetyl-DL-leucine on the activity of the medial vestibular nucleus (MVN) 
and vestibular-related networks have been measured electrophysiologically in an UVL guinea pig 
model (Vibert and Vidal, 2001a). The nature of response depended on the resting membrane 
potential. Acetyl-dl-leucine acted mainly on abnormally hyperpolarized and/or depolarized MVN 
neurons, by bringing back their membrane potential towards a mean value of −65 to −60 mV. 
Because of this stabilizing effect, acetyl-DL-leucine reduced the asymmetry within the 
vestibular-related networks caused by the UVL, decreasing the activity of the MVN neurons on 
the hyperactive intact side and increasing activity on the silent lesioned side, without affecting the 
neurons with a normal membrane potential. This mechanism is most likely mediated by its direct 
interactions with membrane phospholipids such as phosphatidylinositol-4,5-bisphosphate, which 
influences ion channel activity (Suh and Hille, 2008). 
 Studies in humans on the action of acetyl-DL-leucine were in accordance with the animal 
studies (Ferber-Viart et al., 2009). It has been shown that the effect depended on the presence of 
vestibular compensation (VC) before the labyrinthectomy. In patients with almost complete 
vestibular lesion prior to surgery, VC had taken place before the surgery, with vestibular neurons 
having regained a normal resting potential. In this group of UVL patients, no effect of the therapy 
was observed. This study has shown that acetyl-DL-leucine can ameliorate the static component 
of the VC following vestibular deafferentation, without having an effect on the dynamic 
component.  
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 Furthermore, a prior [18F]-Fluoro-desoxyglucose ([18F]-FDG)-µPET study in an UVL rat 
model investigating the regional cerebral metabolic rate for glucose (rCGMglc) revealed that 
only L-isomer or DL-racemate, but not N-acetyl-D-leucine caused a significant acceleration of 
VC, acting in a dose-dependent manner. Moreover, only L-isomer caused a significant increase 
of rCGMglc in the vestibulocerebellum and a decrease in the posterolateral thalamus and 
subthalamic region (see Figure 5) (Günther et al., 2015). This is supported by a recent study, 
focused on the examining of the pharmacological effects of acetyl-DL-leucine in an UVL cat 
model, showing that L-isomer is an active component of the DL-racemate, since it significantly 
accelerates the vestibular compensation process (Tighilet et al., 2015). 
 Studies showed that the calcium homeostatis is dysregulated in NPC disease, similar to 
spinocerebellar ataxias (SCAs), as reflected in the calcium depletion in the late 
endosome/lysosome (Lloyd-Evans et al., 2008). This leads to the functional disturbance of 
Purkinje cells. Since the input from Purkinje cells and mossy/climbing fiber collaterals controls 
the action potential of the vestibular and the cerebellar nuclei (Witter et al., 2011), which in turn 
project to the brainstem, thalamus and spinal cord (Highstein and Holstein, 2006), acetyl-DL-
leucine may act through afferent and efferent projections on upstream and downstream structures, 
thus influencing movement control.  
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Figure 5. Comparison of the N-acetyl-L-leucine effect on regional cerebral glucose 
metabolism following unilateral labyrinthectomy and sham unilateral labyrinthectomy. 
Regional cerebral glucose metabolism (rCGM) on days 1, 3, 7 and 15 between groups treated 
with N-acetyl-L-leucine (24 mg i.v. per rat) after unilateral labyrinthectomy (UL) and after sham 
UL (i.e., without inner ear damage). A) rCGM was significantly decreased in the posterolateral 
thalamus bilaterally on days 3 and 7 and the contralesional subthalamic region on day 3 in the 
UL-group as compared to the sham UL-group. B) On days 3 and 7 rCGM was significantly 
increased in the vestibulocerebellum bilaterally in the UL-group. Abbreviations: R, right; L, left; 
C, caudal; Ro, rostral; Ce, cerebellum; St, subthalamic region; Th, thalamus. P-value < 0.001. 
Adapted from (Günther et al., 2015), open access. 
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 A clinical study in patients with degenerative cerebellar ataxia of different etiologies has 
shown a positive effect on the cerebellar symptomatology, without causing any side effects 
(Strupp et al., 2013). Patients improved significantly on 6 out of 8 sub-scores of the Scale for 
Assessement and Rating of Ataxia (SARA) (gait, speech, finger-chase, nose-finger-test, rapid-
alternating-movements, and heel-to-shin). The evaluation of the Spinocerebellar Ataxia 
Functional Index (SCAFI) showed a better performance in 3 out of 4 elements (8-m-walking-
time, 9-Hole-Peg-Test of the dominant hand and PATA rate). Of note, the objective improvement 
was additionally reflected in the increased quality of life during treatment.  
 Another clinical study demonstrated an improved coefficient of variation of stride time in 
the gait analysis in 14 out of 18 patients with cerebellar ataxia (Schniepp et al., submitted). The 
improvement of variability was restricted to the condition of slow walking, where walking 
stability is thought to critically rely on the sensory integration function of the cerebellum 
(Schniepp et al., 2012). 
In contrast, in a case-series with 10 patients with degenerative cerebellar ataxia, no 
improvement in SARA was observed (Pelz et al., 2015). However, 7 out of 10 patients described 
a subjective improvement on medication. Since at the time of this study, the acetyl-DL-leucine 
tablets were not available, a liquid formulation of 5 g once a day was administered, which may 
account for the failure to confirm the therapeutic benefit. 
 All in all, the beneficial effect of therapy with acetyl-DL-leucine in patients with NP-C 
needs to be confirmed by a randomized, long-term, placebo-controlled, double blind, 2 way 
cross-over phase II clinical trial.  
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Aims of this thesis 
There is no symptomatic or disease-specific therapy for cerebellar ataxia. So far, symptomatic 
treatments with potassium channel blockers azetazolamide and aminopyridines have been 
investigated, improving some of the ataxia symptoms (Claassen et al., 2013a; Kalla et al., 2007; 
Schniepp et al., 2011; Strupp et al., 2003, 2004, 2011). The only recommended therapy in ataxias 
is intensive physiotherapeutic training (Ilg et al., 2014). As such, new therapeutic options are a 
high priority. 
 This cumulative thesis consists of two manuscripts, of which the first one has been 
published in the peer-reviewed journal Neurology®. The second one has also been submitted for 
publication in a peer-reviewed journal and is under review. The aims of this cumulative thesis 
are: First, to explore the effects of acetyl-DL-leucine on cerebellar ataxia symptoms, eye 
movements, and quality of life in patients with NP-C disease. This agent has been shown to 
improve cerebellar symptoms in patients with cerebellar ataxia of different etiologies (Strupp et 
al., 2013). Second, to address the question of whether there is a vestibular deficit in NP-C disease 
or not, which could contribute to the well-known postural imbalance in this disorder.  
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ABSTRACT 
Objective: To assess the effects of the modified amino-acid acetyl-DL-leucine (AL) on 
cerebellar ataxia, eye movements, and quality of life of patients with Niemann-Pick type C (NP-
C) disease.  
Methods: Twelve patients with NP-C disease were treated with AL 3 g/day for 1 week and then 
with 5g/day for 3 weeks with a subsequent wash-out period of 1 month. The Scale for the 
Assessment and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index (SCAFI), 
the modified Disability Rating Scale (mDRS), EuroQol 5Q-5D-5L, and the visual analog scale 
(VAS) were administered. Measurements took place at baseline, after 1 month of therapy, and 
after 1 month of wash-out. 
Results: The SARA score changed from the baseline (median [±SD, interquartile range]) of 10.8 
(11.2, 8-24.6) to 7.0 (10.7, 5.6-19.6) on medication (difference: 3.8 points) and 10.5 (11.5, 7.1-
23.9) after washout (difference: 3.5 points) (p = 0.000412; post hoc p = 0.003 between baseline 
and on-medication, and on-medication and wash-out p = 0.005). The SCAFI subscore 9-Hole Peg 
Test (9HPT) for dominant hand, mDRS score, and VAS score also improved on medication. No 
side effects except transient dizziness in one patient were reported.  
Conclusions: Treatment with AL improved ataxic symptoms in patients with NP-C without 
relevant side effects, thus showing a reasonable risk-benefit profile. 
Classification of evidence: This study provides Class IV evidence that AL improves cerebellar 
symptoms and quality of life in patients with NP-C disease.  
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INTRODUCTION 
 Niemann-Pick type C (NP-C) is a hereditary lysosomal storage disease characterized by 
progressive neurologic deterioration and premature death (Vanier, 2010). The disease presents 
with systemic, psychiatric and neurologic symptoms, including cerebellar ataxia, most 
pronounced in juvenile and adult patients (Mengel et al., 2013; Patterson et al., 2012, 2013).  
 The current disease-specific therapy approved for NP-C is miglustat (Zavesca; Actelion 
Pharmaceuticals Ltd, Allschwil, Switzerland), which targets sphingolipid synthesis and storage 
and thus slows the progression of the disease (Vanier, 1999). However, because of the 
progressive and irreversible nature of the disease, additional symptomatic treatment is needed to 
improve functioning and quality of life and to alleviate the burden of disease.  
 The prior study assessing the effect of therapy with the acetylated derivative of a natural 
amino-acid, acetyl-DL-leucine (AL) (Tanganil; Pierre Fabre, Castres, France) in patients with 
cerebellar ataxia of different etiologies suggested the beneficial effect of this agent (Strupp et al., 
2013). In this study, we evaluated the effect of therapy with AL in patients with genetically 
and/or biochemically proven NP-C disease.  
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SUBJECTS AND METHODS 
Level of evidence. The aim of this Class IV evidence study was to evaluate the effect of AL 3 
g/day for 1 week (Tanganil 500 mg) and then 5g/day for the following 3 weeks (in total, 1 
month) on cerebellar function, ocular motor function, and subjective satisfaction.  
Standard protocol approvals, registration, and patient consents. This case series was an 
observational study. All patients and/or guardians of patients gave their informed consent for the 
compassionate use of AL. Signed patient consent-to-disclose forms were also obtained for videos 
of patients and their family members. 
Patients. Ten patients with genetically confirmed and 2 patients with biochemically confirmed 
NP-C disease (5 females, mean age [±SD] 22.9 ± 4.9 years, mean disease duration 13.7 ± 4.1 
years, mean age when diagnose was established 17.7 ± 5.3 years) were included. The clinical 
characteristics of the patients are given in table 1.  
 
Table 1. Baseline characteristics of the subjects included in the study. 
 
Patient 
no./ 
Sex/Ag
e y 
Age of 
onset/ 
diagnos
is y 
Medication Genotyp
e 
Neurologi
cal and 
psychiatri
c 
findings
a, b 
Internal 
manifestation/ot
her findings
b 
Ocular 
motor 
finding
s
c
 
MRI 
finding
s
d
 
MoC
A
b 
 
IQ
g
 
1/M/13 
 
4.5/ 
10 
Levetiraceta
m 1750 
mg/d, 
valproate 
750 mg/d, 
miglustat 
400 mg/d 
NPC1: 
c.3182T>
C 
c.3557G>
A 
 
a, b, c, d, 
e, f, g, j, k, 
o, p, s, t 
Medium grade 
splenomegaly, 
PEG 
a, b, c, 
e 
b 8 46 
2/F/23
f
 
 
3/19 Levetiraceta
m 300 
mg/d, 
sertraline 
50 mg /d, 
donezepil 
10 mg/d,  
clonazepam 
NPC1: 
c.2861C>
T 
c.3557G>
A 
 
a, b, c, d, 
e, f, h, i, j, 
k, n, o, s, t 
Mild 
splenomegaly, 
cachectic habitus 
a, c, d, 
e 
a, b NcP 33 
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0,5 mg/d, 
miglustat 
600 mg/d 
3/F/26 
 
7/23 Valproate 
600 mg/d, 
miglustat 
500 mg/d 
 
NPC1: 
c.1935du
pT 
c.2861C>
T 
 
a, b, d, e, f, 
g, h, j, k, 
n, o, t, v 
PEG, 
tracheostomy, 
cachectic habitus 
a, b, c, 
d, e 
b NcP 20 
4/F/32 18/28 Sertraline 
50 mg/d, 
vitamin B1, 
B6, B12 
1x/week  
NPC1: 
c.1028G>
A 
c.2198C>
G  
 
b, c, d, f, 
h, j, k, s, t 
Initial 
manifestation 
after birth of her 
child 
a, b, c, 
e  
NP 25 74 
5/F/25 
 
6/22 Miglustat 
600 mg/d 
NPC1: 
c.3019C>
G c.3592-
7_3754-
3delCTT
TT 
b, c, d, f, s, 
t 
Mild 
splenomegaly 
a, b, c, 
e 
b 13 60 
6/M/24 10/21 Miglustat 
600 mg/d, 
hearing 
devices 
bilaterally 
NPC1: 
c.2474A>
G 
c.3160G>
A 
b, c, d, f, 
h, k, l, m, 
s, t 
Splenomegaly a, c n 25 N
P 
7/M/20 
 
8/18 Risperidon 
0.5 mg/d, 
miglustat 
600 mg/d 
No 
mutation 
in NPC1 
and 
NPC2 
genes 
found
e
 
b, c, d, f, 
k, r, s, t 
Mild 
hepatosplenomeg
aly 
a, c  b 23 N
P 
8/M/26 
 
13/13 
 
Levetiraceta
m 200 
NPC1:  
c.1232G>
a, b, c, d, f, 
k, m, n, s, t 
Hepatosplenome
galy 
a, c n 2 46 
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mg/d, 
melatonin, 
miglustat 
C 
c.2861 
C>T  
 
9/M/20
f
 
5/16 Ramipril 
0.125 mg/d, 
metronidaz
ole, 
miglustat 
600 mg/d, 
hearing 
devices 
NPC1: 
c.2861C>
T 
c.3557G>
A  
b, c, d, e, l, 
m, f, t 
Hepatosplenome
galy, arterial 
hypertension, 
microcytic 
anemia 
a, c, d  NP,  
CT 
normal 
24 
 
79 
10/M/2
5/ 
 
12/17 Lamotrigin 
350 mg/d, 
piracetam 
3600 mg/d, 
gingko 
biloba, 
miglustat 
600 mg/d 
NPC1:  
c.808del
G 
c.2861C>
T 
a, b, d, g, i, 
j, b, s, t, u  
Splenomegaly a, b, c, 
e 
b 14 79 
11/M/2
4 
 
14/15 Miglustat 
400 mg/d, 
ginko 
biloba, 
vitamin 
E, piraceta
m 3600 
mg/d 
NPC1:  
c.1723del
G 
c.2861C>
T 
b, c, d, i, r, 
j, k, l, r, s, 
t 
Mild 
splenomegaly 
b, c, d, 
f  
n 18 81 
12/F/1
7 
 
10/11 Vitamin D 
500 I.E./d, 
miglustat 
600 mg/d 
No 
mutation 
in NPC1 
and 
NPC2 
genes 
found
e
 
b, f, i, s, t Splenomegaly a, c, e n 25 N
P 
Abbreviations: CT = Computer Tomography, MRI = Magnetic Resonance Imaging, MoCA = 
Montreal Cognitive Assessment, UEx = upper extremities, LEx = lower extremities, PEG = 
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percutaneous endoscopic gastrostomy, NP = not performed, NcP = not capable of performing the 
task due to physical limitations 
a
Neurological and psychiatric findings: a = epilepsy; b = ataxic stance and gait; c = 
dysmetria/tremor UEx; d = dystonia; e = contractures of Achilles tendons; f = dysphagia; g = 
gelastic cataplexy; h = dyskinesias; i = emotional instability; j = clonus LEx; k = hyperreflexia; l 
= stuttering; m = hearing impairment; n = confined to a wheelchair; o = excessive salivation; p = 
hypomimia; r = organic psychosis; s = dysarthria; t = cognitive impairment; u = logorrhea; v = 
complete anarthria 
 b 
The total possible MoCA score is 30 points; a score of 26 or above is considered normal. Data 
at baseline. 
c
Ocular motor findings: a = slow vertical saccades; b = vertical saccade paresis downward; c = 
impaired vertical smooth pursuit; d = fixation instability, e.g. square wave jerks; e = impaired 
vertical optokinetic nystagmus; f = strabism 
d
MRI findings: a = supratentorial enlarged liquor spaces; b = generalized atrophy; c = cerebellar  
atrophy; d = brainstem atrophy; e = leukodystrophy; n = normal findings 
e
Positive Filipin Staining (variant type) 
f
Family relatives (mothers are cousins) 
g
Full Scale IQ as tested by Wechsler Adult Intelligence Scale Revised or Wechsler Intelligence 
Scale for Children-IV 
 
Evaluations. To evaluate the overall neurologic status in NP-C disease, the modified Disability 
Rating Scale (mDRS) by Pineda et al., 2010 was applied; the mDRS is a 4-domain scale 
(ambulation, manipulation, language and swallowing) in an extended form (Iturriaga et al., 
2006), which also includes seizures and ocular movements, that assesses the severity of the 
disease and monitors the effect of treatment. The following cerebellar function evaluations were 
administered: (1) the Scale for the Assessment and Rating of Ataxia (SARA) (Schmitz-Hübsch et 
al., 2006; Subramony, 2007), an eight-item clinical rating scale (gait, stance, sitting, speech, fine 
motor function and taxis; range 0–40, where 0 is the best neurological status and 40 the worst); 
and (2) the Spinocerebellar Ataxia Functional Index (SCAFI), comprising the 8-m- walking time 
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(8MW) performed by having patients walk twice, as quickly as possible, from one line to another 
excluding turning, the 9-Hole Peg Test (9HPT) and the number of “PATA” repetitions over 
10 seconds (PATA) (Schmitz-Hübsch et al., 2008).  
Subjective impairment and quality of life were evaluated by using the EuroQol 5Q-5D-5L 
questionnaire (EQ-5D-5L) (Devlin and Krabbe, 2013) and the visual analog scale (VAS). To 
assess the effect of the therapy on ocular motor function, 3-dimensional video-oculography 
(EyeSeeCam) (Glasauer et al., 2003) was used to measure the peak velocity of saccades, gain of 
smooth pursuit, slow phase velocity of gaze-evoked nystagmus (gaze-holding function) (SPV), 
SPV of optokinetic nystagmus, and gain of horizontal vestibulo-ocular reflex at each visit 
(Schneider et al., 2009). To evaluate the potential treatment effect, administration of the SCAFI 
scale in patients with NP-C disease was recorded on video (for 9HPT examination see videos 1 
and 2 on the Neurology® Web site at Neurology.org). Measurements and questionnaire 
administration took place at baseline, after 1 month of therapy with AL (on day 30 ± 1 day), and 
after a 1-month washout period (on day 60 ± 2 days). To evaluate the cognitive state, the 
Wechsler Adult Intelligence Scale-Revised (WAIS-R) or Wechsler Intelligence Scale for 
Children-IV (WISC-IV) (Grove, 1950), and Montreal Cognitive Assessment (MoCA) 
(Nasreddine et al., 2005), assessing different cognitive domains, including attention and 
concentration, executive functions, memory, language, visuoconstructional skills, conceptual 
thinking, calculations, and orientation with a maximum of 30 points and a cut-off score of 26, 
were administered once at baseline ± 1 month (see table 1).  
Patients and their parents were asked about their subjective improvement on medication; videos 
of their subjective evaluation of the effect treatment and possible side effects (see video 3) were 
also recorded. Drug administration and neurological examination (with one exception: WAIS-
R/WISC-IV) were performed by one examiner (T.B.). 
Statistical analysis. Statistical analysis and figure design were performed using SPSS version 
22.0.0 (IBM, Armonk, NY). Differences were considered significant if p < 0.05. Because data 
were not normally distributed, related-samples Friedman test with χ
2 
test statistics was run to 
determine whether there were differences in measured scores between baseline, on-medication 
and washout time-points. Post hoc analysis with the Wilcoxon signed-rank test was conducted 
with a Bonferroni correction. Spearman rank correlation coefficient was used to assess the 
relationships between tested variables. Patients who were not physically capable of performing 
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the particular score tasks were not included in the analysis.  
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RESULTS  
Effects of AL on neurologic status. The total SARA score was 10.8 (11.2, 8-24.6) at baseline 
(median [±SD, IQR]), 7.0 (10.7, 5.6-19.6) after one month of medication (difference: 3.8 points), 
and 10.5 (11.5, 7.1-23.9) after one-month of wash-out (difference: 3.5 points) (for individual 
value changes, see table e-2, figures 1, A and B), indicating an improvement of cerebellar signs 
on medication (χ
2
(2) = 15.591, p = 0.000412). The post hoc testing revealed a statistically 
significant difference between the baseline and the on-medication scores (p = 0.003) and between 
the on-medication and the wash-out scores (p = 0.005), but no significant difference between the 
baseline and the wash-out scores (p = 0.561).  
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Figure 1. Effect of treatment with acetyl-DL-leucine 5 g/d on neurologic status in patients 
with Niemann-Pick type C. Individual and value changes on the Scale for the Assessment and 
Rating of Ataxia (SARA) (A, B) and the modified Disability Rating Scale (mDRS) (C, D). 
Measurements performed at baseline, after 1 month on medication with acetyl-DL-leucine 5 g/d, 
and after 1 month of wash-out. The total SARA score changed significantly from the baseline 
(median [±SD, IQR]) of 10.8 (11.2, 8-24.6) to 7.0 (10.7, 5.6-19.6) after one month of medication 
(difference 3.8 points) and 10.5 (11.5, 7.1-23.9) after one month of wash-out (difference 3.5 
points), indicating an improvement of cerebellar signs on medication (χ2(2) = 15.591, p = 
0.000412). The total mDRS score (median, [±SD, IQR]) was 10.0 (5.35, 7-23) at baseline, 9.0 
(5.3, 6-23) on medication (difference 1 point), and 10.0 (5.4, 6-23) after 1 month of wash-out 
(difference 1 point). This change was statistically significant (χ2(2) = 13.04, p = 0.001). The 
length of the boxes (B, D) indicates the interquartile space (P25–P75), the horizontal line into the 
box represents the median (P50) and the whiskers indicate the adjacent values. The circle 
indicates the outlier. Figure modified for the purposes of this thesis.  
 
 
The SCAFI 9HPT of the dominant hand changed significantly (χ
2
(2) = 6.889, p = 0.032), yielding 
significant differences between baseline and on medication (p = 0.038) as well as on medication 
and wash-out (p = 0.033), but not between baseline and wash-out (p = 0.594). There was a 
general trend for improvement of the 9HPT of the non-dominant hand (p = 0.121) and 8MW (p = 
0.178) on medication. The PATA score did not change significantly between measurements (p = 
0.406) (table e-2, figures 2, A-D).  
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Figure 2. Effect of treatment with acetyl-DL-leucine 5 g/d on cerebellar status in patients 
with Niemann-Pick type C, as assessed by the SCAFI. Boxplot representation of cerebellar 
function, as assessed by the Spinocerebellar Ataxia Functional Index (SCAFI) subscore items 8-
m Walk (8MW) test time (A), 9-Hole Peg Test time for dominant (9HPTD) (B) and non-
dominant (9HPTN) (C) hand, and PATA word count in 10 seconds (D) before, during, and after 
therapy with acetyl-DL-leucine 5 g/d. The SCAFI 9HPTD item changed significantly (χ
2
(2) = 
6.889, p = 0.032) yielding significant differences between baseline and on medication (p = 0.038) 
as well as on medication and wash-out (p = 0.033), but not between baseline and wash-out (p = 
0.594). There was a general trend for improvement of 9HPTN (p = 0.121) and 8MW test (p = 
0.178) on medication. The PATA score did not change significantly between measurements (p = 
0.406). The length of the boxes indicates the interquartile space (P25–P75), the horizontal line 
into the box represents the median (P50) and the whiskers indicate the adjacent values. The 
circles indicate the outliers and the stars represent an extreme value. Figure modified for the 
purposes of this thesis.  
 
The total mDRS score (median [±SD, IQR]) was 10.0 (5.35, 7-23) at baseline, 9.0 (5.3, 6-
23) on medication (difference: 1 point), and 10.0 (5.4, 6-23) after one-month of wash-out 
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(difference: 1 point) (table e-2 and figures 1, C and D). This change was statistically significant 
(χ
2
(2) = 13.04, p = 0.001). The post hoc testing revealed a statistically significant difference 
between the baseline and the on-medication scores (p = 0.01) and between the on-medication and 
the wash-out scores (p = 0.024), but no significant difference between the baseline and the wash-
out scores (p = 0.083). There was a negative correlation between the neurologic and cognitive 
status when the baseline mean total SARA score and IQ score was analyzed ( = -0.756, p < 
0.05). Correlation analysis also showed a trend for a significant association between MoCA and 
SARA scores ( = -0.622, p = 0.055) and MoCA and mDRS scores ( = -0.579, p = 0.079). 
Ocular motor function. The mean peak velocity (±SD, range) of the vertical saccades was 55.0 
°/s (67.2, 35.8-111.3) at baseline, 71.0 °/s (24.3, 44.0-82.0) on medication and 44.0 °/s (19.7, 
33.0-50.0) after one month of wash-out, p = 0.244). The other ocular motor parameters tested 
also did not significantly change (overall comparisons): p for peak velocity of horizontal 
saccades: 0.846, smooth pursuit gain: vertical: 0.554, horizontal: 0.115; p for slow phase velocity 
(SPV) of gaze-evoked nystagmus: vertical: 0.761, horizontal: 0.717; p for horizontal vestibulo-
ocular reflex gain: 0.692; SPV of optokinetic nystagmus: vertical: 0.311, horizontal: 0.692. 
Quality of life. Quality of life, as assessed by EQ-5D-5L, changed from a baseline of 0.62 (0.35-
0.83) to 0.72 (0.43-0.83) on medication and 0.52 (0.19-0.85) without medication (p = 0.459) (see 
table e-2 and figure 3A). VAS changed significantly on medication (p = 0.05), rising from 30 
(25-70) at baseline to 45 (35-80) on medication (p = 0.02). After one month of therapy, VAS 
decreased to 30 (20-60) (p = 0.776) (see table e-2 and figure 3B).  
Subjective evaluation. Family and caregivers of 8 out of the 12 patients believed that there was 
improvement in one or more areas. Parents of 3 out of 12 patients described remarkable 
behavioral improvement in affect stabilization, cooperation, and ability to act independently in 
daily life (e.g. dressing, grooming, drawing). In 3 patients, subjective improvement of dysphagia 
was also reported (fewer swallowing problems whilst drinking and eating). In one patient with 
square wave jerks (SWJ), subjective improvement of fixation, as reported by the parents, was 
observed (see table e-2).  
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Figure 3. Effect of treatment with acetyl-DL-leucine 5 g/d on the quality of life of patients 
with Niemann-Pick type C. Boxplot representation of the value changes on the EuroQol 5Q-5D-
5L questionnaire (EQ-5D-5L) (A) and the visual analog scale (VAS) (B). EQ-5D-5L, assessing 
the quality of life, changed from a baseline of 0.62 (0.35-0.83) to 0.72 (0.43-0.83) on medication 
and 0.52 (0.19-0.85) without medication (p = 0.459). VAS changed significantly on medication (p 
= 0.05), rising from a baseline of 0.30 (0.25-0.70) to 0.45 (0.35-0.80) on the treatment (p = 0.02). 
After one month of therapy, VAS decreased to 0.30 (0.20-0.60) (p = 0.776). The length of the 
boxes indicates the interquartile space (P25–P75), the horizontal line into the box represents the 
median (P50) and the whiskers indicate the adjacent values. Figure modified for the purposes of 
this thesis.  
 
Side effects. One patient reported intermittent dizziness on the dosage of 5 g/day, which ceased 
after the dose was reduced to 3 g/day for one week. When the dosage was increased again, the 
symptoms did not recur.  
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DISCUSSION 
The major findings of this case series are as follows: first, the modified amino-acid acetyl-DL-
leucine (AL) had a significant effect on cerebellar signs and symptoms in patients with 
genetically and/or biochemically proven NP-C disease. Second, the improvement of neurologic 
status also led to a significant improvement of the quality of life of the patients and their family 
members. Third, the low frequency (1 out of 12) and the temporary nature of the adverse effects 
suggest a reasonable risk-benefit profile.  
Acetyl-DL-leucine has been used in France since 1957 to treat acute vertiginous symptoms; 
however, despite a number of proposed hypotheses, including a stabilization of membrane 
potential, its pharmacologic and electrophysiologic modes of action have not yet been clarified 
(Ferber-Viart et al., 2009; Vibert and Vidal, 2001a; de Waele et al., 1990). A fluorodeoxyglucose 
(FDG)-µPET study in a rat model of acute unilateral vestibular lesions demonstrated a significant 
effect of the N-acetyl-L-leucine enantiomer on postural compensation by means of an activation 
of the vestibulocerebellum and a deactivation of the posterolateral thalamus (Günther et al., 
2015). Clinically, the improvement of cerebellar symptoms in humans in a case series with 
cerebellar patients of different etiologies indicated the therapeutic efficacy of AL (Strupp et al., 
2013). Furthermore, a PET study in patients with ataxia of different etiologies given AL 
demonstrated an increased metabolism in the midbrain and lower brainstem in responders 
(Becker-Bense et al., personal communication). Targeting vestibular together with cerebellar 
regions is probably one of the key actions of AL. Impaired central vestibular function in patients 
with NP-C is very likely in light of the well-known ocular motor (Abel et al., 2009) and hearing 
dysfunction (King et al., 2014), even though the vestibulo-ocular reflex, representing the 
peripheral vestibular function seems to be intact (Solomon et al., 2005). However, no evidence 
regarding vestibular function in patients with NP-C disease has been gained so far and its 
improvement might also be responsible for the positive effect of the therapy. 
       In our cohort of patients with NP-C, AL stabilized stance and gait with a lowered risk of 
falls, and improved dysmetria and intentional tremor, thus improving fine motor function. This 
had an impact on the daily activities of patients with NP-C, also reflected in increased quality-of-
life scores on medication. Improvement of dysarthria and dysphagia was not a consistent finding, 
probably because of concomitant bulbar syndrome, and considerable impaired cognition, because 
this leads to absence of communication in some patients. This was also reflected in the fact that 
neurologically more severely affected patients also had a notably lower IQ with a lowered MoCA 
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score. Because patients with NP-C present with a heterogeneous symptomatology, ranging from 
palliative cases unable to act independently to a very mild presentation with isolated slow vertical 
saccades (Garver et al., 2007), the test results and reactions to treatment vary considerably. 
Cognitive impairment and psychiatric comorbidities, such as affective lability with pathologic 
crying or psychotic presentation with aggressive traits, and the abovementioned frequent 
generalized dystonia, and – in later stages – spasticity impeded clinical evaluation of the therapy 
effect. Of note, a slight stabilization of the affect, increase of drive, social interaction, and 
improved performance of complex tasks such as dressing or drawing, on medication was reported 
by parents and rehabilitation staff (see video 3). This might be a secondary effect of the positive 
influence on overall neurologic function; nevertheless, a specific, but as yet unclear effect on 
distinct areas responsible for higher cognitive functions and emotions, such as the frontotemporal 
lobe or the limbic system should also be taken into consideration. 
No remarkable effect of AL therapy on ocular motor function has been noted, especially not on 
the supranuclear ocular motor centers in the brainstem; however, an improvement of fixation by 
diminishing the intensity of square wave jerks might suggest a positive effect on cerebellar ocular 
motor centers. This is in line with the previously shown and abovementioned increase of regional 
cerebral metabolic rate for glucose in the vestibulocerebellum (Günther et al., 2015) and 
brainstem (Becker-Bense et al., personal communication). 
       The only side effect of the medication was transient, dose-dependent dizziness in one of the 
12 patients, thus demonstrating a good risk-benefit profile of the medication. 
       Our study has several limitations. First, this is an observational study with all its limitations 
and not a randomized, placebo-controlled trial. Therefore, a placebo effect or a training effect on 
components of ataxia assessment (e.g., 9HPT) cannot be ruled out. Second, the long-term 
efficacy of AL was not evaluated. Therefore, a longer-term, placebo-controlled, double-blind, 
randomized clinical trial of AL in a larger cohort of patients with NP-C is necessary to assess its 
safety and effects on disease progression. Third, in 2 of the 12 patients, no mutation was found. 
        This observational study demonstrated that AL had a positive effect on ataxia in patients 
with NP-C, improved their quality of life, and was well tolerated. Since the mechanism of the AL 
action is not thought to be NP-C specific, if AL showed benefit in a placebo-controlled trial in 
NP-C or any other disease with prominent ataxia, it might be generally useful across all ataxias. 
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Supplemental material 
 
Supplemental Table e-2 
Patient no. 
 
mDRS 
 
SARA 8MW 9HPTD 9HPTN PATA EQ-5D-5L 
Profile/Index 
Value 
 
VAS Subjective 
improvement* 
 
a. baseline 
b. on medication 
c. after 1 month of titration 
1 a 16 25.5 16 127 116 3.5 55533/0.063 30  
1 b 16 21 18.1 108 128 10.5 45533/0.275 30 No 
1 c 16 25 24.3 155.8 148.7 3 44543/0.260 20  
2 a 17 30 32.3 NcP NcP NcP  55553/-0.14 23  
2 b 14 23.5 28 137 NcP NcP  44431/0.493 39 Yesa, b, d, f, g, h, i 
2 c 17 32.5 68.5 NcP NcP NcP  55543/-0.02 18  
3 a 23 40 NcP NcP NcP NcP 55532/0.063 40  
3 b 23 39 NcP NcP NcP NcP 55521/0.085 85 Yesb 
3 c 23 40 NP NP NP NP NP NP  
4 a 12 8 7.8 51.5 69 15.5 44423/0.515 25  
4 b 11 7 6.7 60 45.1 11.5 43433/0.563 40 Yesa, b, c, d, h, i 
4 c 12 7 6.5 57.5 61.5 10.5 44423/0.515 30  
5 a  8 8 4.9 66.7 49.7 8 32211/0.828 55  
5 b 7 6 4.7 61.5 54.4 9 32312/0.828 60 No 
5 c 7 6 5.9 72.6 67.3 10 33312/0.194 60  
6 a  8 10.5 6.9 51.1 73.4 12.5 32211/0.828 50  
6 b 6 5.5 6 44.5 67.7 13 32331/0.716 45 No 
6 c 8 11 5.7 44.4 81.7 13 32311/0.828 60  
7 a 7 11 6.2 85 158.2 10 33421/0.62 30  
7 b 6 8 5.6 72.9 154 13 22222/0.755 60 Yesa, b, d, e 
7 c 6 10.5 6.2 82.5 171.5 13 22311/0.845 50  
8 a 18 22 11.97 NcP NcP 5.5 44443/0.351 20  
8 b 16 15.5 11 NcP NcP 4.5 34442/0.374 30 Yesa, b, c, d, f, h, i 
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Clinical assessment of patients by the modified Disability Rating Scale (mDRS), the Scale for the 
Assessment and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index (SCAFI), 
comprising the 8-m-Walking-Time (8MW), 9-Hole-Peg-Test (9HPT) and the number of “PATA” 
repetitions over 10 s (PATA), the EuroQol 5Q-5D-5L questionnaire (EQ-5D-5L), and the visual 
analog scale (VAS) at baseline, on medication, and after one month of wash-out.  
Abbreviations: mDRS modified Disability Rating Scale, SARA Scale for the Assessment and 
Rating of Ataxia, SCAFI Spinocerebellar Ataxia Functional Index, 8MW 8-m-Walking-Time, 
9HPTD 9-Hole-Peg-Test of the dominant hand, 9HPTN 9-Hole-Peg-Test of the non-dominant 
hand, PATA PATA word repetition test in 10 s, EQ-5D-5L Euro Quality of Life Scale, VAS 
Visual Analog Scale 
NcP not capable of performing the task due to physical limitations 
NP not performed for other reasons 
* Subjective improvement on medication, as assessed by parents: a = stance; b = gait; c = tremor; 
d = fine motor function; e = speech disturbance; f = swallowing; g = ocular movements, e. g. 
square wave jerks; h = social interaction; i = self-care, e. g. eating, grooming, dressing, going to 
the toilet 
8 c 17 20.5 13.35 NcP NcP 6 45442/0.194 20  
9 a 7 3.5 5 38.9 38.5 18.5 11121/0.910 70  
9 b 
9 c 
7 
7 
3.5 
4.5 
4.5 
5.4 
32.3 
36.1 
36.7 
33.6 
20 
18 
11121/0.910 
11121/0.91 
80 
70 
Yesa, b, d 
10 a 11 10 9.7 79.6 108.9 7.5 22312/0.845 90  
10 b 10 7 7.1 62.7 64.5 9 22311/0.845 80 No 
10 c 11 7.5 6.5 74.2 62.1 5 12211/0.930 95  
11 a 9 12 5.6 99.5 150.6 13.5 33343/0.491 30  
11 b 8 6 6.8 73 64.5 15 43434/0.430 35 Yesc, d, e 
11 c 9 10.5 5.1 80.5 125.0 15.5 43334/0.48 30  
12 a 7 7 5.9 27.7 41.1 14 32223/0.738 70  
12 b 7 5.5 5 19.3 23.7 12.5 22223/0.76 90 Yesa, b, c, d, e, h 
12 c 
 
7 9.5 7.5 19.5 25 11.5 32334/0.53 30  
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Supplemental video legends 
Videos can be found on the attached CD at the end of this thesis. 
 
Video 1 
9-Hole-Peg Test of the dominant hand of patient 11 at baseline, on medication and after one 
month of wash-out. 
 
Video 2  
9-Hole Peg Test of the dominant hand of the patient 2 at baseline, on medication and after one 
month of wash-out. 
 
Video 3 
Interview with the parents of Niemann-Pick type C patients describing the effects of the 
treatment with acetyl-DL-leucine on the neurological function and acting in daily life. 
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Abstract 
We investigated whether vestibular dysfunction is the cause or may cause or contribute to 
postural imbalance and falls in patients with Niemann-Pick type C disease (NP-C). Eight patients 
with NP-C disease and 20 healthy controls were examined using the video-based head impulse 
test (vHIT) and caloric irrigation to investigate horizontal canal function as well as ocular- and 
cervical vestibular evoked myogenic potentials (o- and cVEMP) and binocular subjective visual 
vertical estimation (SVV) for otolith function, and static posturography. There were no significant 
differences in vestibulo-ocular gain, caloric excitability, o-/cVEMP measures or SVV between 
the two groups. Posturographic total sway path (tSP) and root mean square (RMS) were 
significantly higher in NP-C than in controls in 3 out of 4 conditions. The Romberg quotient 
(RQ) to assess the amount of visual stabilization was significantly lower in the NP-C than in the 
HC group.  
In contrast to other inherited metabolic disorders, such as Morbus Gaucher type 3, we did not 
find any evidence for an impairment of canal or otolith function in patients with NP-C as their 
cause of postural imbalance. Since RQ was low in NP-C patients, indicating proper sensory input, 
the observed increased postural sway is most likely due to a cerebellar dysfunction in NP-C, 
which may therefore explain postural imbalance.  
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INTRODUCTION 
Niemann-Pick type C (NP-C) is a rare, multisystemic disease caused by pathological lipid storage 
and presenting with systemic, neurologic and psychiatric symptoms (Vanier, 2013). The cardinal 
symptom in all disease forms is vertical supranuclear saccade palsy, leading to complete gaze 
palsy in some patients, found in 70% of patients from an international disease registry (Patterson 
et al., 2013), but other ocular motor systems can also be impaired (Abel et al., 2009; Rottach et 
al., 1997). One of the most prominent neurologic symptoms, especially in juvenile and adult 
forms, is postural imbalance and gait disorder with recurrent falls. This may be due to impaired 
vestibular function, i.e. bilateral vestibulopathy (as in Morbus Gaucher type 3 (Chen et al., 2014) 
or chronic progressive external ophthalmoplegia (Ritchie et al., 2010)), cerebellar ataxia 
(Patterson et al., 2013) or a combination of both as in cerebellar ataxia, neuropathy, vestibular 
areflexia syndrome (CANVAS) (Kirchner et al., 2011; Szmulewicz et al., 2011). 
A vestibular deficit is plausible, because hearing is also impaired in patients with NP-C. A prior 
study showed high-frequency sensorineural hearing loss with retrocochlear involvement, with for 
hearing aids required at least in later stages of the disease (King et al., 2014) but, in the prior 
sibling studies, a normal vestibulo-ocular reflex (VOR) was observed (Lengyel et al., 1999; 
Solomon et al., 2005).  
Intact function of the vestibular, proprioceptive and cerebellar systems is necessary for good 
balance and postural stability, which can be assessed by posturography (Krafczyk et al., 2006). 
With this tool, identification of the nature of the balance disturbance and topo-anatomical 
differentiation of the cerebellar impairment are possible (Diener et al., 1984). 
The function of the vestibular system can be easily quantified nowadays. The angular VOR 
(aVOR) gain, defined as the ratio of eye velocity to head velocity, can be assessed by the video-
based head impulse test (vHIT) in the high-frequency range (Agrawal et al., 2014) and by caloric 
irrigation in the low-frequency range (Halmagyi et al., 2000). Otolith function can be examined 
by ocular vestibular evoked myogenic potentials (oVEMP) for the utricle (Curthoys et al., 2012) 
and cervical VEMP for the saccule (Rosengren and Kingma, 2013). Furthermore, graviceptive 
pathways can be assessed by examination of the static subjective visual vertical (SVV) with the 
help of the bedside bucket test (Zwergal et al., 2009). In this study, we systematically examined 
the function of the vestibular system and postural balance in a cohort of eight patients with NP-C 
using the abovementioned clinical tools.  
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METHODS 
Subjects. This study was conducted at a large tertiary outpatient clinic for vestibular and ocular 
motor disorders. Six patients with genetically confirmed and two patients with biochemically 
confirmed NP-C disease (2 females; age 27.3 ± 10.4 years (mean±SD), range 17-51 years, mean 
age of onset 9.4 ± 4.4 years, mean age at diagnosis 18.4 ± 13.8 years, mean disease duration 18 ± 
12.4 years) were included. Results were compared with those of twenty age-matched healthy 
controls (HC) (11 females, 28.0 ± 10.9, range 11-57 years), with no history of vestibular, neuro-
ophthalmologic or neurologic disease. Patients’ demographic and clinical characteristics are 
summarized in table 1. Clinical data of 5 out of 8 patients have been reported elsewhere 
(Bremova et al., 2015). 
 
Table 1. Demographic and clinical characteristics of Niemann-Pick type C patients. 
 
Patient 
Nr/ 
Sex/Age 
y 
Age of 
onset/dia
gnosis 
y/disease 
duration 
Medicati
on 
Genoty
pe 
Neurolog
ic and 
psychiatr
ic 
findingsa 
Internal 
manifestation/ 
other findings 
Tibial 
nerve 
SSEP 
/vibrati
on sense 
LE 
Ocular 
motor 
findingsb 
MRI 
findi
ngsc 
MoC
Ad 
 
mDR
Se 
 
SAR
Af 
1/M/24 
 
10/21/14 Miglustat 
600 mg/d, 
hearing 
devices 
bilateral 
NPC1: 
c.2474A
>G 
c.3160G
>A  
b, c, d, f, 
h, k, l, m, 
s, t, y 
Splenomegaly Prolong
ed 
latencies 
L>R 
Bilateral 
8/8  
a, c, e, 
h 
n 25 8 11 
2/M/20 
 
8/18/12 Miglustat 
600 mg/d, 
risperidon
e 0.5 
mg/d 
No 
mutatio
n in 
NPC1 
and 
NPC2 
genes 
foundg 
b, c, d, f, 
k, r, s, t 
Mild 
hepatosplenome
galy 
Prolong
ed 
latencies 
bilateral 
Radial 
6/8 R, 
5/8 L, 
malleola
r 6/8 R, 
5/8 L 
a, c, e b 23 7 10.5 
3/F/51 
 
40/49/11 Miglustat 
600 mg/d, 
hearing 
devices 
NPC1: 
c.2621A
>T 
c.2872C
>T  
b, c, i, k, 
m, s, r, t 
Mild 
splenomegaly 
NP a, b, c, 
e, g, h 
a NP 6 4 
4/M/28 
 
1/1/27 Miglustat 
600 mg/d, 
NPC1: 
c.3182T
b, c, d, f, 
s, t, y 
Hepatosplenome
galy 
N a, c, h a, c, d 24 5 5 
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xipamid 
2.5 mg/d, 
aliskiren 
150 mg/d 
>C 
c.3182T
>C 
5/F/17 
 
10/11/7 Miglustat 
600 mg/d 
vitamin D 
500 I.E./d 
No 
mutatio
n in 
NPC1 
and 
NPC2 
genes 
foundg 
b, f, i, s, t Splenomegaly N 
 
a, c, e n 25 9 7 
6/M/25/ 
 
12/17/13 Miglustat 
600 mg/d, 
lamotrigi
ne 350 
mg/d, 
piracetam 
3600 
mg/d, 
gingko 
biloba  
NPC1:  
c.808del
G 
c.2861C
>T 
a, b, d, g, 
i, j, k, o, 
p, s, t, u, 
y, z  
Splenomegaly N a, b, c, 
e, h 
b, f 14 9 7.5 
7/M/24 
 
14/15/10 Miglustat 
400 mg/d, 
ginko 
biloba, 
vitamin 
E, piracet
am 3600 
mg/d 
NPC1:  
c.1723d
elG 
c.2861C
>T 
b, c, d, i, 
j, k, l, r, s, 
t, y, z, ac, 
ad, ae 
Mild 
splenomegaly 
Prolong
ed 
latencies 
bilateral, 
decrease
d 
amplitud
es 
Bilateral 
5/8 
b, c, d, 
f, h 
n 18 9 10.5 
8/M/29 
 
 
14/15/16 Miglustat 
300 mg/d, 
olanzapin
e 20 
mg/d, 
magnesiu
m 
NPC1:  
c.2861C
>G 
c.3433T
>C 
b, c, d, f, 
i, j, k, p, r, 
s, t, u, y, 
z, ac, ae 
Splenomegaly  N a, b, c, 
d, e, g, 
h 
n 9 
 
13 19 
 
Abbreviations: L = left, LE = lower extremities, MoCA = Montreal Cognitive Assessment, 
mDRS = modified Disability Rating Scale, MRI = Magnetic Resonance Imaging, N = normal, NP 
= not performed, R = right, SARA = Scale for the Assessment and Rating of Ataxia, SSEP = 
Somatosensory evoked potentials. 
a 
Neurologic and psychiatric findings: a = epilepsy; b = ataxic stance and gait; c = dysmetria; d = 
dystonia; e = contractures of Achilles tendons; f = dysphagia; g = gelastic cataplexy; h = 
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dyskinesias; i = emotional instability/depression; j = clonus lower extremities; k = hyperreflexia; 
l = balbuties; m = hearing impairment; n = confined to a wheelchair; o = excessive salivation; p = 
hypomimia; r = organic psychosis; s = dysarthria; t = cognitive impairment; u = logorrhea; v = 
complete anarthria; x = developmental delay; y = tremor upper extremities; z = acatisia; aa = 
myoclonia; ab = hypofonia; ac = daily somnolence; ad = panic attacks; ae = verbal 
aggressiveness. 
b 
Ocular motor findings: a = slow vertical saccades; b = vertical saccade paresis downward; c = 
impaired vertical smooth pursuit; d = fixation instability, e.g. square wave jerks; e = impaired 
vertical optokinetic nystagmus; f = strabism; g = slow horizontal saccades; h = impaired 
horizontal smooth pursuit. 
c 
MRI findings: a = supratentorial enlarged liquor spaces; b = generalized atrophy; c = cerebellar  
atrophy; d = brainstem atrophy; e = leukodystrophy; f = periventricular signal enhancement; n = 
normal findings; g = calcifications. 
d 
The total possible Montreal Cognitive Assessement (MoCA) score is 30 points; a score of 26 
and higher is considered normal. 
e 
The lowest possible modified Disability Rating Scale (mDRS) score is 0 points; the highest is 
24. 
f 
The lowest possible score of the Scale for the Assessment and Rating of Ataxia (SARA) is 0, the 
highest possible score is 40 points.  
g 
Positive Filipin Staining (variant type). 
 
Neurological examination. All patients received a thorough neurologic, neuro-ophthalmologic 
and neuro-otologic examination. To evaluate the overall status of NP-C disease, the modified 
Disability Rating Scale (mDRS) (Iturriaga et al., 2006; Pineda et al., 2009) was administered; 
cerebellar function was assessed by administration of the Scale for the Assessment and Rating of 
Ataxia (SARA) (Subramony, 2007; Weyer et al., 2007). Neurologic examination furthermore 
involved: examination of the cranial nerves, examination of the reflexes of the upper and lower 
extremities with pyramidal signs and extremity tonus. Proprioception was assessed clinically by 
tuning fork examination, with a normal finding rated as 6-8/8 and pathological proprioception 
rated as <5/8, and electrophysiologically by measuring somatosensory evoked potentials (SSEP) 
of the tibial and median nerves. Neuropsychologic status was assessed by the Montreal Cognitive 
Assessment (Nasreddine et al., 2005). All patients underwent brain magnetic resonance imaging 
(MRI) (see table 1). 
Neuro-ophthalmologic and neuro-otologic examination comprised examination with and without 
Frenzel’s glasses to detect nystagmus, gaze-evoked nystagmus, head-shaking nystagmus, smooth 
pursuit, saccades, and optokinetic nystagmus. 
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Ocular and cervical vestibular evoked myogenic potentials (o/cVEMP). We used the same 
methodology as the one employed in previous studies (Agrawal et al., 2013; Bremova et al., 
2013). For oVEMP, subjects lay in a supine position and were instructed to foveate a red dot 
fastened at the minishaker margin during oVEMP stimulation. Tap stimuli were delivered with a 
Bruel and Kjaer Mini-Shaker Type 4810 (2-ms clicks of positive polarity, with a repetition rate of 
2 per second) at the midline of the hairline, 30% of the distance between the inion and nasion. 
The recording electrode was positioned over the inferior oblique muscle bilaterally, 
approximately 3 mm below the eye and centered beneath the pupil; a reference electrode was 
placed on the chin and a ground electrode under the chin. The responses to 50-100 stimuli were 
averaged. n1 and p1 were identified as the first negative and positive peaks that occurred between 
10 and 20 ms after stimulus onset (Jongkees et al., 1962). For cVEMP, participants were 
instructed to lift their heads with active straining of the sternocleidomastoid muscles on both 
sides to provide tonic background muscle activity during stimulation and recording. Air-
conducted 500-Hz, 100-dB SPL tone bursts were delivered monaurally via intra-auricular 
headphones. Cervical VEMP were recorded from an electrode montage consisting of a recording 
electrode placed at the midpoint of the ipsilateral sternocleidomastoid muscle belly, a reference 
electrode placed on the manubrium sterni, and a ground electrode placed on the forehead. p1 and 
n2 peaks were identified as the first positive and negative peaks that occurred between 13 and 23 
ms after stimulus onset. Peak-to-peak (PP) amplitudes, calculated as the sum of p1 and n2 peaks, 
were then divided by mean electromyographic activity recorded after the stimulus onset in order 
to check for background muscle activity. Corrected cVEMP PP amplitudes and p1 latencies were 
evaluated.  
 
Video-based head impulse testing (vHIT). The aVOR gain (eye velocity/head velocity) (Aw et 
al., 1996), assessed by the administration of the HIT with the EyeSeeCam system (Schneider et 
al., 2009), was evaluated. Eye and head movements were recorded monocularly on the left eye 
with 2-dimensional video-oculography (VOG) (Bartl et al., 2009). Each participant was 
instructed to binocularly foveate a visual target comprising a visual angle of 0.3° presented in the 
center of the 22” large computer monitor (LG, FLATRON W2242PK–SS, LG Electronics, 
Germany) running at 60 Hz. Monitor luminance was 250 cd/m
2
. The monitor was positioned 60 
cm from the participant’s nasion and subtended a visual angle of 43.2° horizontally by 27.7° 
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vertically. Eye dominance was not determined. The VOG system was calibrated for each 
participant by recording eye fixations at the central and eccentric positions aligned in 8.5° array 
across a range of ±15°. Calibration recordings were visually inspected to exclude artifacts. 10±2 
head impulses were performed to each side.  
 
Caloric testing. Caloric testing was performed with bithermal caloric irrigation (water 
temperature 30° and 44°, duration of irrigation 30 s). Patients lay in a supine position with their 
heads turned to the opposite ear during the measurement. Caloric-induced nystagmus was 
recorded for 2 minutes by means of the VOG system (EyeSeeCam® (Schneider et al., 2009). To 
calculate the slow-phase velocity (SPV) of the caloric-induced nystagmus, eye velocity was 
calculated using numerical three-point differentiation of eye position and subsequent Gaussian 
low-pass filtering with a corner frequency of 30 Hz. The high-frequency velocity peaks of 
nystagmus quick phases, saccades and blink artifacts were removed from eye velocity using an 
absolute acceleration threshold and subsequent floating median filter with a time window of 0.25 
s. For robust extreme value (maximum or minimum) determination, the squared fit was 
calculated from the SPV data window (±15 s about the extrema), which was previously filtered 
by a zero-phase digital filter. The peak slow-phase velocity (PSPV) of the caloric-induced 
nystagmus was calculated as an extreme value of the fitted curve.  
All patients underwent caloric irrigation; the results of the caloric testing of 3 out of 8 patients 
(patients no. 3, 6 and 8) were not quantitatively analyzed due to non-compliance or artifacts. 
Directional preponderance was calculated using the standard Jongkees formula (Jongkees et al., 
1962) and PSPV values <5°/s were considered pathological. The asymmetry ratio was considered 
abnormal when ≥25%.  
 
Subjective visual vertical (SVV). SVV was determined by binocular estimation of the dark 
straight line at the bottom of the bucket which was rotated clockwise or counterclockwise. A 
mean of 10 measurements, exceeding the range of values 0±2.3°, was considered a criterion for a 
pathological SVV tilt (Zwergal et al., 2009). 
 
Posturography. Posturographic examination was performed in the upright position with eyes 
open and closed, on firm ground (conditions 1 and 2) and on a slab of foam rubber (conditions 3 
and 4) (Krafczyk et al., 2006). 
   Vestibular function in NP-C 
47 
 
The total body sway (tSP) in 30 seconds of the posturographic measurement, expressed as the 
sway path values [m/min], root mean square (RMS) [mm] and frequency spectrum between 2.4-
3.5 Hz (Fast Fourier Transform, FFT) of the z axis (head-vertical) (kgf/Hz) of the measurements 
were analyzed. The Romberg quotient (RQ), a ratio of the tSP with eyes closed and open, to 
assess the amount of visual stabilization, was calculated (Njiokiktjien and Van Parys, 1976). 
 
Statistical methods. Statistical analysis and figure design were performed using SPSS version 
22.0.0 (IBM, New York, NY, USA) and MATLAB (The Mathworks Inc). Differences were 
considered significant if p < 0.05. Normality of data distribution was tested using the mean, 
median, standard deviation and visual inspection of normal Q-Q plots and box plots. As data 
were not normally distributed, Wilcoxon related-samples rank test and non-related samples 
Mann-Whitney-U test were conducted. To assess the relationships between tested variables, 
Spearman rank correlation coefficient was used. Patients who were not physically capable of 
performing the particular score tasks or who did not perform the test for other reasons were 
excluded from the analysis.  
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RESULTS 
Angular VOR. Representative raw data of a patient with NP-C and an HC subject are presented 
in figure 1A. The mean aVOR gain in patients with NP-C was 1.07 ± 0.12 and in controls 1.10 ± 
0.12 (p = 0.469) (see figure 2A): There were no statistically significant relationships with other 
vestibular and neurologic tests (SVV: ρ = 0.250, p = 0.589; oVEMP n1 amplitude: ρ = 0.069, p = 
0.727; cVEMP PP amplitude: ρ = 0.163, p = 0.408; SARA: ρ = -0.198, p = 0.670; mDRS: ρ = 
0.146, p = 0.729). There was also no correlation with age (ρ = 0.157, p = 0.426), disease duration 
(ρ = 0.405, p = 0.320) or age of onset (ρ = 0.217, p = 0.606).  
 
Figure 1. Angular vestibulo-ocular reflex, ocular and cervical vestibular evoked myogenic 
potentials in a patient with Niemann-Pick type C and a control. Representative raw traces of 
the angular vestibulo-ocular reflex (aVOR) (A), ocular and cervical vestibular evoked myogenic 
potentials (o- and cVEMP) (B) of a patient with Niemann-Pick type C (patient no. 5) and a 
healthy control. The blue line (1A) represents the mean of performed video-based head impulse 
tests (vHIT). The red line (1B) indicates the function of the otolith organs on the left side, the 
blue line of those on the right side.  
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Caloric irrigation testing. Mean PSPV of caloric-induced nystagmus was 18.5 ± 6.8 °/s in 
response to warm water and 12.6 ± 5.3 °/s in response to cold water. After excluding the patient 
who suffered a left labyrinth contusion with bleeding in 2008 after a bike accident with a left-side 
canal paresis with PSPV of 2°/s (patient no. 6), the asymmetry ratio was 10 ± 1.6%. 
 
Ocular and cervical VEMP. Representative raw data of the NP-C and HC subjects are presented 
in figure 1B. Mean oVEMP n1 amplitude was 11.5 ± 5 µV in NP-C and 12.0 ± 4.8 µV (p = 
0.784) in HC groups. Mean oVEMP n1 latency was 12.1 ± 1.5 ms in NP-C patients and 10.8 ± 
3.1 ms (p = 0.199) in HC subjects. Mean corrected cVEMP PP amplitude was 1.07 ± 0.5 µV in 
NP-C and 1.1 ± 0.5 µV in HCs (p = 0.862). Mean cVEMP p1 latency was 16.3 ± 1.4 ms in NP-C 
and 16.6 ± 1.4 ms in HC groups (p = 0.980). A graphical representation of the VEMP data is 
shown in figures 2B and 2C.  
Correlation analysis also showed no significant relationships between age of onset (oVEMP n1 
amplitude: ρ = -0.639, p = 0.088; n1 latencies: ρ = -0.012, p = 0.977; cVEMP PP amplitudes: ρ = 
-0.566, p = 0.143; p1 latencies: ρ = 0.446, p = 0.268) and o- and cVEMP amplitudes and 
latencies, as well as duration of disease (oVEMP n1 amplitudes: ρ = 0.190, p = 0.651; n1 
latencies: ρ = 0.262, p = 0.531; cVEMP PP amplitudes: ρ = 0.190,  p = 0.651; p1 latencies: ρ = -
0.238, p = 0.570) and o- and cVEMP amplitudes and latencies.  
There was no relation between neurological status, as assessed by mDRS and SARA and o-
/cVEMP parameters in NP-C patients (mDRS: oVEMP n1 amplitude: ρ = -0.586, p = 0.127, n1 
latency: ρ = -0.073, p = 0.863; cVEMP PP amplitudes: ρ = -0.488, p = 0.220, p1 latency: ρ = 
0.610,  p = 0.108; SARA: oVEMP n1 amplitude: ρ = -0.419, p = 0.301, n1 latency: ρ = -0.299, p 
= 0.471; cVEMP PP amplitudes: ρ = -0.275, p = 0.509, p1 latency: ρ = 0.575, p = 0.136).  
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Figure 2. Angular vestibulo-ocular reflex, ocular 
and cervical vestibular evoked myogenic 
potentials amplitudes and latencies in patients 
with Niemann-Pick type C and controls. Box plot 
representation of the angular vestibulo-ocular reflex 
(aVOR) gain (A), ocular vestibular evoked myogenic 
potentials (oVEMP) n1 amplitudes and n1 latencies 
respectively (B) and cervical VEMP peak-to-peak 
(PP) amplitudes and p1 latencies (cVEMP) (C) in 
patients with Niemann-Pick type C disease (NP-C) 
and healthy controls (HC). The light green depicts the 
VEMP amplitudes in HC, the dark green depicts the 
latencies in HC. The light blue depicts the VEMP 
amplitudes in NP-C and the dark blue depicts the 
VEMP latencies in NP-C. No statistically significant 
differences between the NP-C and HC groups were 
found for the vestibular measurements. The length of 
the boxes indicates the interquartile space (P25–P75); 
the horizontal line into the box represents the median 
(P50) and the whiskers indicate the adjacent values. 
The circles indicate the outliers. 
 
 
Subjective visual vertical. SVV was tilted in 3 out 
of 8 patients with NP-C. The mean SVV was -0.18 ± 
2.9 ((95% CI for the mean) -2.87 to +2.51) and was 
thus slightly higher than the range described 
previously (Zwergal et al., 2009). There was no 
significant relationship with any of the tests.  
 
Posturography. Condition 1 (standing on firm 
ground with eyes open): The tSP was 1.8 ± 0.7 (1.2-
2.4) m/min in NP-C patients (mean±SD, (95% CI for 
the mean)) and 0.7 ± 0.1 (0.7-0.8) m/min in controls 
(Z = -3.818, p = 4.5x10-6) (difference: 1.1 m/min), 
the RMS was 12.5 ± 5.2 (7.7-17.3) mm in NP-C 
patients and 4.9 ± 1.9 (4.0-5.8) mm in controls (Z = -
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3.375, p = 2.117x10-4) (difference: 7.6 mm). The integral of the frequency spectrum (FFT Z) was 
36.9 ± 41.6 (-1.6-75.4) kgf/Hz in NP-C patients and 7.3 ± 3.5 (5.6-8.9) kgf/Hz in controls (Z = -
1.881, p = 0.06).  
Condition 2 (standing on firm ground with eyes closed): The tSP was 1.8 ± 0.7 (1.1-2.4) m/min in 
NP-C patients and 0.9 ± 0.1 (0.8-1) m/min in controls (Z = -3.818, p = 4.504x10-6) (difference: 
0.9 m/min), the RMS was 9.4 ± 5.1 (4.7-14.1) mm in NP-C patients and 5.2 ± 1.9 (4.0-6.1) mm in 
controls (Z = -2.434, p = 0.013) (difference: 4.2 mm). The FFT Z was 19.4 ± 18.9 (1.9-36.9) 
kgf/Hz in NP-C patients and 6.1 ± 1.8 (5.3-7) kgf/Hz in controls (Z = -3.150, p = 0.002). 
Condition 3 (standing on foam with eyes open): The tSP of NP-C patients yielded 3.8 ± 2.8 (1.3-
6.4) m/min and tSP of controls 1.2 ± 0.3 (1.1-1.3) m/min (difference: 2.6 m/min) (Z = -2.43, p = 
1.486x10-4). The RMS was 20 ± 6.6 (13.9-26.1) mm in NP-C patients and 8.3 ± 2.7 (7-9.6) mm 
in controls (difference: 11.7 mm) (Z = -3.486, p = 1.013x10-4). The FFT Z was 123.1 ± 131.5 
(1.4-244.7) kgf/Hz in NP-C patients and 33 ± 12.8 (27-39) kgf/Hz in controls (Z = -1.771, p = 
0.077). 
Condition 4 (standing on foam with eyes closed): The tSP of NP-C patients yielded 4.8 ± 2.5 
(2.5-7.2) m/min and in controls 3.3 ± 1 (2.8-3.7) m/min (difference: 1.5 m/min) (Z = -1.439, p = 
0.162). The RMS was 24.9 ± 7.6 (17.9-32) mm in NP-C and 19.6 ± 27 (16.2-22.9) mm in 
controls (difference: 5.5 mm) (Z = -1.605, p = 0.109). The FFT Z was 132.8 ± 93.8 (46.1-219.5) 
kgf/Hz in NP-C patients and 98.2 ± 42.6 (77.6-118.7) kgf/Hz in controls (Z = -0.665, p = 0.506). 
The amount of visual stabilization, as assessed by the RQ on both firm ground and foam was 
significantly different across the groups, being higher in controls (firm ground: NP-C 1.01 ± 0.24 
(0.8-1.2), HC 1.27 ± 0.25 (1.2-1.4) p = 0.022; foam: NP-C 1.4 ± 0.6 (0.9-1.9), HC 2.7 ± 0.8 (2.4-
3.1), p = 2.117x10-4).  
In one patient, discrete cerebellar 3 Hz postural sway was seen (patient no. 4 in table 1). This 
finding has a morphological correlate in a cerebellar atrophy, as seen in MRI. 
The frequency plot of an NP-C patient, a patient with a cerebellar 3-Hz sway and a healthy 
subject is shown in figure 3A, and a graphical representation of the tSP and RMS values is 
presented in figure 3B.  
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Figure 3. Posturographic results in patients with Niemann-Pick type C and healthy 
controls. Frequency plot of the z axis (kgf/Hz) in a patient with Niemann-Pick type C (NP-C) 
(blue line), a patient with cerebellar sway (red line) and a normal subject (green line) standing on 
foam with eyes closed (3A). Note that the frequency pattern of the NP-C patient is not 
significantly different from that of a healthy subject with a normal frequency distribution. Bar 
representation of the differences in total sway path (tSP) and root mean square (RMS) values in 
patients with Niemann-Pick type C and healthy controls (3B).   
* indicates significant difference at the 0.05 level 
** indicate significant difference at the 0.001 level 
 
Correlation analyses. There was no significant association between neurologic status, as 
assessed by mDRS and SARA, and posturographic parameters in NP-C patients (mDRS: tSP in 
condition 1: ρ = 0.296, p = 0.518, RMS: ρ = 0.074, p = 0.875; tSP in condition 2: ρ = 0.222, p = 
0.632; RMS: ρ = 0.667, p = 0.102, tSP in condition 3: ρ = -0.037, p = 0.937, RMS: ρ = 0.259, p = 
0.574; tSP in condition 4: ρ = -0.074, p = 0.875, RMS: ρ = 0.185, p = 0.691; SARA: tSP in 
condition 1 ρ = 0.559, p = 0.192, RMS: ρ = 0.721, p = 0.068; tSP in condition 2: ρ = 0.126, p = 
0.788; RMS: ρ = 0.631, p = 0.129, tSP in condition 3 ρ = -0.180, p = 0.699, RMS: ρ = 0.487, p = 
0.268; tSP in condition 4: ρ = -0.595, p = 0.159, RMS: ρ = 0.523, p = 0.229). 
No significant relationships between the posturographic and VEMP parameters, but one (tSP 
value in condition 4 and cVEMP PP amplitudes) were seen (oVEMP n1 amplitude: tSP in 
condition 1: ρ = 0.170, p = 0.397, RMS: ρ = 0.192, p = 0.338; tSP in condition 2: ρ = -0.036, p = 
0.858; RMS: ρ = -0.125, p = 0.536, tSP in condition 3: ρ = 0.148, p = 0.462, RMS: ρ = 0.191, p = 
0.340; tSP in condition 4: ρ = 0.001, p = 0.998, RMS: ρ = 0.155, p = 0.440; cVEMP PP 
amplitudes: tSP in condition 1: ρ = -0.001, p = 0.998, RMS: ρ = 0.018, p = 0.930; tSP in 
condition 2: ρ = -0.150, p = 0.455; RMS: ρ = -0.270, p = 0.172, tSP in condition 3: ρ = 0.015, p = 
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0.940, RMS: ρ = 0.051, p = 0.799; tSP in condition 4: ρ = -0.384, p = 0.048, RMS: ρ = -0.281, p 
= 0.155). 
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Table 2. Posturographic results in Niemann-Pick type C patients and healthy controls. 
 
Groupa Nb Condition 
1c 
tSP 
[m/min] 
 
Condition 
1 
RMS 
[mm] 
 
Condition 
1 
FS 
FFT Z 
[kgf/Hz] 
 
Condition 
2d 
tSP 
[m/min] 
 
Condition  
2 
RMS 
[mm] 
 
Condition 
2 
FS 
FFT Z 
[kgf/Hz] 
 
Condition 
3e 
tSP 
[m/min] 
 
Condition 
3 
RMS 
[mm] 
 
Condition 
3 
FS 
FFT Z 
[kgf/Hz] 
 
Condition 
4f 
tSP 
[m/min] 
 
Condition 
4 
RMS 
[mm] 
 
Condition 
4 
FS 
FFT Z 
[kgf/Hz] 
 
RQg 
Firm 
ground 
 
RQ 
Foam  
 
NP-C 
 
7 
 
 
1.8 (0.7) 
1.7 (1.1)  
 
12.5 (5.2) 
13 (7.8) 
 
36.9 (41.6) 
19.6 (54.8) 
1.8 (0.7) 
1.6 (1.5) 
9.4 (5.1) 
9.3 (6.8) 
19.4 (18.9) 
10.8 (18.3) 
3.8 (2.8) 
3.1 (1.8) 
20 (6.6) 
21.6 (9.7) 
123.1 
(131.5) 
101.8 (97.1) 
4.8 (2.5) 
4.7 (3.8) 
24.9 (7.6) 
27.7 (10.3) 
132.8 (93.8) 
100.7 (168) 
1.02 
(0.24) 
0.96 
(0.47) 
1.42 (0.55) 
1.41 (0.68) 
HC 20 0.7 (1.1) 
0.8 (0.2) 
4.9 (1.9) 
4.3 (2.6) 
7.3 
(3.5) 
6.3  
(3.2) 
0.9 (1.4) 
0.8 (0.2) 
5.2 (1.9) 
4.8 (2.1) 
6.1 
(1.8) 
5.9 
(2.3) 
1.2 (0.3) 
1.2 (0.2) 
8.3 (2.7) 
7.8 (3.9) 
33 
(12.8) 
29.5 
(16.3) 
3.3 (1) 
3.3 (1.5) 
19.6 (7.1) 
18.2 (10.9) 
98 
(42.6) 
96 
(72.3) 
1.27 
(0.25) 
1.26 
(0.33) 
2.75(0.83) 
2.7 (1.51) 
P-value  4.504x10-6 2.117x10-4 0.06 4.504x10-6 0.013 0.002 1.486x10-4 1.01x10-4 0.077 0.162 0.116 0.506 .022 2.117x10-4 
Abbreviations: HC = healthy controls, IQR = interquartile range, FFT Z = Fast Fourier Transform of the z axis, FS = frequency 
spectrum, RQ = Romberg quotient, tSP = total Sway Path, RMS = Root Mean Square.  
a 
Parameters are depicted as mean (standard deviation) and median (interquartile range), 
b 
All patients, but one (patient no. 7) underwent 
posturographic measurements, 
c
 Standing on firm ground with eyes open, 
d
 Standing on firm ground with eyes closed, 
e 
Standing on foam 
with eyes open, 
f
 Standing on foam with eyes closed, 
g 
Romberg quotient (RQ)- a ratio of the total sway path with eyes closed to eyes 
open. 
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Discussion 
The major findings of this study are as follows: first, we did not find any evidence for an 
impairment of angular VOR function (in either the high-frequency or in the low-frequency range) 
or otolith function (in either the utricle or the saccule); second, patients showed remarkable 
postural instability compared with normal subjects; third, analysis of the posturographic findings 
indicated diffuse cerebellar disturbance with potential involvement of the vestibulo-cerebellum. 
Based on our results, vestibular horizontal canal and otolith function is intact.  
These findings were unexpected in light of the fact that the vestibular system is commonly 
affected in neurodegenerative disorders (Shaikh et al., 2011; Strupp et al., 2014). In fact, in 
another lysosomal storage disease, Gaucher disease type 3 (neuronopathic type, GD3), impaired 
otolith pathways and aVOR deficits with absent horizontal refixation saccades were described 
(Chen et al., 2014). This might be explained by the neuronal loss and functional disturbance of 
the vestibular nuclei in the medulla and paramedian pontine reticular formation (PPRF) 
respectively, leading to horizontal saccade palsy in GD3 disease. Vestibular nuclei and their 
afferent and efferent projections seem to be functionally intact in NP-C disease. The specific 
pattern of impairment in NP-C and GD3 diseases suggests a different neuronal susceptibility to 
the toxic effects of the storage material. The intact vestibular organs are also reflected in a lack of 
correlation between any of the vestibular tests and clinical rating scales.  
In terms of posturography, we found that patients with NP-C had increased body sway 
compared with controls in 3 out of 4 conditions. Disturbance of the somatosensory input in 
condition 4 led to an equal increase of the total sway path in both groups. The effect of vision was 
significantly more pronounced in controls, since the Romberg quotient was significantly higher in 
controls than in patients with NP-C. This finding also indicates the functionally intact vestibular 
organs, as visual cue is known to be of high importance in peripheral vestibulopathy to 
compensate for the vestibular loss (Krafczyk et al., 2006; Nashner et al., 1982). Moreover, due to 
the saccadic deficits, motor performance and orientation in space that require visual-vestibular 
interaction in patients with NP-C are impaired. It is likely that the balance network compensates 
for these ocular deficits by enhancing the other sensory input, especially vestibular and 
somatosensory input. Balance is not based on a fixed set of equilibrium reflexes but on a flexible, 
functional motor skill that can adapt with training and experience and presumably reflects noise 
and regulatory activity within afferent-efferent control loops, which are plastic enough to 
compensate for the existing deficits. 
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Visual stabilization had no remarkable influence on the postural stability, as indicated by 
the low Romberg quotient of the total sway path in patients with NP-C, even though the 
proprioception was diminished in 3 patients. A low proportion of visual stabilization suggests that 
the spino-cerebellum and its spinal afferents are not primarily affected by the disease process. 
Nevertheless, atrophy of the cerebellar vermis in severe cases of NP-C disease has been 
previously described (Fusco et al., 2012; Huang et al., 2011). 
In the frequency analysis, there was no consistent 3 Hz anteroposterior cerebellar sway in patients 
with NP-C. One patient with cerebellar atrophy in MRI had increased postural sway at 2-3 Hz 
frequency, but he did not reach values seen in patients with anterior lobe lesions (Diener et al., 
1984). 
All in all, the constellation of the posturographic findings (pathological sway parameters 
with poor visual stabilization without 3 Hz sway) suggests a rather diffuse cerebellar disturbance 
with a possible involvement of the vestibulo-cerebellum, rather than isolated impairment of the 
spino-cerebellum, anterior lobe or cerebellar hemispheres (Diener et al., 1984; Schwesig et al., 
2009). In contrast, a patterned degeneration of the Purkinje cells from anterior to posterior, with 
surviving Purkinje cells in lobules IX and X at the terminal stages of the disease has been 
described in an NP-C mouse model (Sarna et al., 2003). Our NP-C cohort was relatively young 
(mean age = 27.3 years, mean SD = 10.4 years) with a rather mild cerebellar disturbance (mean 
SARA score 9.3/40) and lacking severe involvement of any circumscribed region of the 
cerebellum. Thus, the pattern of neurodegeneration described in the mouse model could not be 
observed. 
The isolated cerebellar impairment without vestibular involvement is also in line with 
previously shown increased metabolism in the vestibulo-cerebellum in a rat model of peripheral 
vestibulopathy under therapy with acetyl-DL-leucine (Günther et al., 2015). The beneficial effect 
of this therapy was seen recently in a cohort of 12 NP-C patients (Bremova et al., 2015), 
improving stance and gait, diadochokinesis and diminishing the intensity of the square wave 
jerks, indicating a stabilizing effect on impaired cerebellar Purkinje cells, similar to the effect on 
neurons of medial vestibular nucleus in an unilateral-vestibular-loss guinea-pig model (Vibert and 
Vidal, 2001b). This study has some limitations. First, the sample size is small, given that the NP-
C disease is an orphan disease, meaning that this study might be underpowered. Second, as 
patients become fatigued very quickly, some tests were not performed due to the lack of 
compliance or due to physical disability or cognitive impairment. Third, there is an ongoing 
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discussion about the sensitivity and specificity of VEMP investigation, principally because of its 
high interindividual, but also interrater variability (Ertl et al., 2015). 
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Discussion 
Within the framework of this thesis, two aspects of NP-C disease have been investigated. First, 
we evaluated the effect of treatment with the amino-acid acetyl-DL-leucine on cerebellar 
symptoms, eye movements and quality of life. Second, we evaluated the function of the 
vestibular system in patients with NP-C versus healthy controls, and its contribution to postural 
imbalance, including topo-anatomical assessement of the quantitative posturographic measures. 
For these two studies, patients with NP-C had to be recruited from 3 European countries 
(Germany, Slovakia, Czech Republic) and were systematically examined.  
 A plethora of techniques were used. Patients were assessed clinically by means of clinical 
rating scales (Scale for the Assessment and Rating of Ataxia, the Spinocerebellar Ataxia 
Functional Index, modified Disability Rating Scale, Montreal Cognitive Assessement, ED-5Q-5L 
Quality of Life with visual analog scale). Further, different types of eye movements were 
examined video-oculographically (saccades, smooth pursuit, gaze-holding, optokinetic 
nystagmus in horizontal and vertical planes), and video-head impulse test to measure the function 
of the high-frequency angular vestibulo-ocular reflex. And last, but not least, cervical and ocular 
vestibular evoked myogenic potentials to measure the function of the saccule and utricle, as well 
as posturography with a neuronal network analysis to measure postural imbalance and the 
underlying cause, were applied. 
 
1.3 Effects of the therapy with acetyl-DL-leucine in patients with NP-C disease 
We treated a cohort of 12 patients with NP-C disease with amino-acid acetyl-DL-leucine for 4 
weeks. We were able to show that: first, the modified amino-acid acetyl-DL-leucine had a 
significant effect on cerebellar signs and symptoms in patients with genetically and/or 
biochemically proven NP-C disease. Second, the improvement of neurologic status also led to a 
significant improvement of the quality of life of the patients and their family members. Third, the 
therapy also improved the cognitive function and functioning in daily life, in terms of a slight 
stabilization of emotional affect, an increase in drive and social interaction, as well as improved 
performance of complex tasks, such as dressing or drawing. Fourth, the low frequency (1 of 12) 
and the temporary nature of adverse effects suggested a reasonable risk-benefit profile.  
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The limitations of this study were a) a lack of a reference agent (placebo), b) the non-
blinded design, c) small sample size and the short observational period. Thus, in a future project, 
we aim to prove the effect of medication under these conditions (see the section 1.4.1.2). 
 Current state of knowledge indicates that acetyl-DL-leucine restores the normal 
membrane potentials of both hyper- and depolarized neurons (Vibert and Vidal, 2001a). Since 
there is evidence for calcium dyshomeostasis in NP-C disease, within particular functionally 
disturbed Purkinje cells, similar to SCAs, restoring the calcium equilibrium within the cerebellum 
might be the actual mode of action in NP-C.  
 This is supported by the fact that we found no evidence for a vestibular disturbance in 
patients with NP-C in our second study. We hypothesize that the effect of the therapy is probably 
due to the direct action on Purkinje cells in the cerebellum, rather than on the intact vestibular 
centers in the brainstem.  
 All in all further studies focusing on the action of acetyl-DL-leucine in both humans and 
animal models are a high priority.  
1.4 Vestibular function and postural balance in patients with NP-C disease 
In the second study, we were able to show that horizontal aVOR and otolith functions are, in 
contrast to other lysosomal storage disorders such as GD3, intact in patients with NP-C. This was 
suprising in light of the documented deficits in GD3 disease which exhibits decreased VOR gain, 
increased latency and absence of refixation saccades (Chen et al., 2014). 
 Moreover, saccular function was partially diminished and utricular function was fully 
diminished in GD3 patients, which was also not the case in patients with NP-C. This indicates 
that even though the origin of both disorders is a well-known failure of the degradation of 
lysosomal material, the way lipid storage causes the pattern of neurodegeneration seen in NP-C 
and GD3 is still not fully understood. 
 A Fourier analysis of posturographic data revealed that the stance and gait unsteadiness is 
indeed of cerebellar origin, with possible involvement of the vestibulo-cerebellum (flocculo-
nodular lobe), rather than isolated impairment of the spino-cerebellum, vermis or cerebellar 
hemispheres, even though proprioception was diminished in some patients. There was also no 
characteristic 3 Hz cerebellar sway, seen in patients with vermis atrophy (Sullivan et al., 2010). 
Since our NP-C cohort was relatively young (mean age = 27.3 years, SD = 10.4 years), there was 
no severe involvement of any particular cerebellar region, underlying high-grade ataxia (mean 
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SARA score 9.3/40). This might be biased by patient selection, since the severely affected 
palliative patients were not able to participate in the study, due to the motor, but also cognitive 
deficits. Thus, we did not observe the common pattern of neurodegeneration, beginning in 
lobules I and II and progressing from anterior to posterior, relatively sparing the vestibulo-
cerebellum described in the mouse model of NP-C disease (Sarna et al., 2003).  
 Although the patients with NP-C disease present hearing and ocular motor deficits, arising 
from the specific impairment of the cochlear and vertical saccadic centers in the brainstem, based 
on our results the central and peripheral vestibular centers are intact. From a clinical perspective, 
the saccadic system, which reflects the disease dynamics, rather than the vestibular system, can 
be used to track the disease progress and therapy effect at patients` follow-up.  
1.4.1 Further investigations, work in progress and perspectives in NP-C disease  
1.4.1.1 Systematic and standardized explorative, multicenter, observational ocular motor 
study 
The hallmark and initial symptom of NP-C disease is the vertical supranuclear saccade palsy 
(VSSP). In the course of disease, smooth pursuit also deteriorates, leading to a gaze restriction 
and a vertical supranuclear gaze palsy (VSGP). The VSGP has been found in 70% of patients in 
an international patient registry (Patterson et al., 2013). Nevertheless, to detect the VSSP, both 
saccades and smooth pursuit have to be examined. This depends on the clinical expertise, so that 
an actual prevalence of the VSSP in patients with NP-C might be considerably higher, based on 
our expert experience possibly yielding 95%.  
The saccadic function in NP-C disease has been investigated in previous works (Abel et 
al., 2009; Lengyel et al., 1999; Solomon et al., 2008), nevertheless, these studies suffer from 
limitations. First, given the rarity of the disease studies often have a small number of participants, 
and thus these studies might be underpowered. Second, the course of the disease is highly 
variable, so that generalisations about ocular motor findings across the NP-C population based on 
the observations in siblings might lack validity. Third, eye movement examinations might be 
reduced in quality with some older eye-tracking systems (such as infra-red systems), so that new 
studies using new video-oculographic tools are required to re-evaluate the already existing 
findings.  
 Thus, we are currently analysing ocular motor data of the largest prospectively examined 
NP-C cohort of 31 NP-C patients, measured across four European countries (Germany, Italy, 
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Czech Republic, Slovak Republic) by means of the video-oculographic tool (EyeSeeCam®) 
(Schneider et al., 2009). Given its non-invasivity, simplicity and time-efficiency, which 
considerably increase the patient compliance, children could also be measured (Figure 6). 
Horizontal and vertical saccades, smooth pursuit, gaze-holding, optokinetic nystagmus and 
horizontal angular VOR were examined. Moreover, in order to relate and compare the ocular 
motor impairment with the clinical status, clinical rating scales, including mDRS, SARA, SCAFI 
and MoCA were administered.  
 
                          
Figure 6. Mobile video-oculographic set-up allows non-invasive measurement of pediatric 
patients. 
 
 This study has a considerable impact in terms of future diagnostic and screening studies.  
On the one hand, it has identified the particular challenges and confounding factors of this 
examination in a large, genetically heterogeneuos cohort of pediatric and adult patients with NP-
C. The examination is challenging both for the considerable ocular motor deficits found in these 
patients (gaze palsy), their compensation strategies (blinking, head movements), but also because 
of their sometimes very restricted cognitive abilities. Since the problems seen in the video-
oculographic examination can be observed also in other neurodegenerative disorders such as 
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Gaucher disease type 3 or ataxia telangiectasia, this set-up can be used broadly in a clinical 
routine, meaning that the data collected multicentricaly is consistent and of minimal variability. 
On the other hand, since it is non-invasive, it can also be used to screen for patients with 
neurodegenerative disorders, who initially demonstrate subtle ocular motor changes, such as slow 
vertical saccades in NP-C. This is of great importance, especially in treatable metabolic diseases, 
where establishing a diagnosis implies the administration of a disease-specific therapy, such as 
miglustat in NP-C, which has been shown to at least slow the progression of the disease and thus, 
prolong the life expectancy of these patients (Patterson M et al., 2015). 
On top of the abovementioned benefits of this pilot examination, we aim to: first, 
characterize the ocular motor systems more in detail, describing the so-called saccadic patterns. 
Second, establish the link between the saccadic patterns and clinical phenotype. Third, correlate 
the quantitative ocular motor parameters and patterns with the phenotype assessed by the clinical 
rating scales to find potential ocular motor biomarkers that may serve as clinical outcome 
measures for future clinical trials.  
1.4.1.2 Explorative, multicenter, cross-sectional longitudinal ocular motor study in 
patients with NP-C 
In addition to the abovementioned study, a longitudinal standardized and systematic ocular motor 
study to assess the progress of disease and response to treatment, is currently in preparation. A 
cohort of 50 to 100 patients from Germany, France, Czech Republic, Italy, Spain, Russia, Brazil 
and Iran, together with the same number of gender and age-matched controls will be ocular motor 
and neurologically examined. Horizontal and vertical reflexive and self-paced saccades will be 
used to evaluate the function of the supranuclear brainstem structures (riMLF and PPRF) together 
with cortical areas for saccade generation (Frontal Eye Field, FEF for voluntary saccades and 
Pariental Eye Field, PEF for reflexive saccades). Moreover, gaze-holding in eccentric positions to 
evaluate the function of cerebellar flocculo-nodular lobe and supranuclear brainstem structures 
(Ncl. interstitialis Cajal, INC for vertical and Nucleus praepositus hypoglossi, NPH for horizontal 
gaze-holding), as well as smooth pursuit to evaluate the function of cerebellum and pontine 
nuclei, will be performed. To compare the ocular motor systems with clinical status, mDRS will 
be administered and subsequently correlated with a battery of ocular motor parameters, including 
saccadic peak velocity, mean velocity, amplitude, gain, latency, acceleration, peak duration, 
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mean duration as well as the slopes of linear regression line of the analyzed parameters, smooth 
pursuit gain, slow-phase velocity of gaze-holding nystagmus (if present).  
 
1.4.1.3 Therapy of lysosomal storage disorders (Niemann-Pick disease type C and Gaucher 
disease type 3) with acetyl-DL-leucine: Randomized, double-blind, placebo-
controlled, 2 way cross-over phase II NGAT trial  
Based on the initial studies with acetyl-DL-leucine for treatment of cerebellar ataxia in patients 
with NP-C and degenerative cerebellar ataxia syndromes, we are currently planning a 
randomized, double-blind, placebo-controlled, 2 way cross-over phase II trial. The added value of 
these clinical studies is the demonstrated safety and tolerability of the agent in different medical 
conditions with a common symptom of cerebellar ataxia. As mentioned above, the limitations of 
these studies are a) a lack of the reference agent (placebo), b) the non-blinded design, c) small 
sample size and the short observational period. Thus, this project aims to prove the effect of 
medication under these conditions in patients with NP-C and GD3.  
Although miglustat helps to stabilize the neurological involvement in NP-C (Patterson et 
al., 2015), evidence that miglustat stabilizes the cerebellar ataxia is still lacking. Furthermore, 
enzyme replacement therapy (ERT) ameliorates the systemic manifestations, but has no effect on 
the neurological involvement in GD3, stressing the importance of alternative therapies in this 
disorder (Vellodi et al., 2009).  
In this study, we aim to evaluate the efficacy of acetyl-DL-leucine in patients with 
genetically and/or biochemically diagnosed NP-C and GD3 older than 5 years of age with SARA 
more than 2 points. A reference intervention will be treatment with placebo in double-blind 
fashion (for study design, also see Figure no. 7). Duration of intervention per patient will be 
sixteen weeks in total, including 2x4 weeks of verum/placebo in cross-over design, 4 weeks 
wash-out between both treatment periods and follow-up visit after 4 weeks.  
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Figure 7. Intervention scheme of the NGAT trial with study visits. 
 
1.4.1.4 Clarifying the action of acetyl-DL-leucine in vivo and in vitro  
Our clinical study to evaluate the effects of the therapy with acetyl-DL-leucine in patients with 
NP-C has demarcated some emerging implications in basic science research, especially in the 
field of cell biology.  
Calcium dyshomeostasis in the late endosome/lysosome occurs in NP-C disease, 
establishing a link between NP-C disease and spinocerebellar ataxias (SCAs) (Lloyd-Evans et al., 
2008).  
To date, the lysosomal cell biology group around Dr. Lloyd-Evans at Cardiff University, 
UK has identified that there is a role for changes in Ca
2+
 signalling as one potential mechanism 
explaining how acetyl-DL-leucine works in NP-C disease cells. There is evidence that acetyl-DL-
leucine acts via an extracellular Ca
2+
 sensing receptor (CaSR), which preferentially binds 
positively charged L-configurated amino-acids. Our collaborators in Cardiff observed that there 
is a reduction in storage in NP-C cells treated with acetyl-DL-leucine and that if the Ca
2+
 
concentration is changed, no benefit in the NP-C cells can be observed. Moreover, they have also 
found that this benefit correlates with expression of CaSR.  
Furthermore, calbindin is a Ca
2+
 binding protein and a useful marker in NP-C disease as 
in NPC1 it is secreted in high levels into the CSF and plasma, thus reflecting the changes in Ca
2+
 
that occur in NP-C cells. If acetyl-DL-leucine changes intracellular Ca
2+
 levels via CaSR 
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regulation then there might be changes in the levels of calbindin in plasma, confirmed by ELISA. 
For the lipids, if acetyl-DL-leucine is altering Ca
2+
 levels then there might be some normalisation 
of lipid storage, which can be confirmed by the lipidomics. 
The aim of this work in progress is to evaluate whether the reduced lipid levels in the 
patient samples (and changes in the Ca
2+
 binding protein calbindin) are in line with the cell 
culture findings, providing clinical reference for the mechanism found. This might also clarify 
how acetyl-DL-leucine works for other disorders such as SCA, since by altering Ca
2+
 sensing 
receptor function, cellular Ca
2+
 levels will change. 
The changes in Ca
2+
, CaSR and calbindin can be subsequently correlated with the changes 
in the clinical rating scales before and after therapy with acetyl-DL-leucine.  
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1.5 1Conclusion 
We showed in an observational study that a therapy with the modified amino acid acetyl-DL-
leucine improves cerebellar ataxia and quality of life in patients with NP-C disease. These 
findings are the basis for a planned multinational randomized, placebo-controlled, double-blind, 
2-way cross-over phase II trial in patients with NP-C and GD3. Further, the therapeutic effect of 
acetyl-DL-leucine seen in our case series stimulated collaboration with colleagues UK who are 
now looking for its binding sites, changes of calcium homeostasis and lipid storage as well as its 
impact on ion channels. These findings will also have implications for the explanation of the 
pathophysiology of NP-C. 
We demonstrated that – in contrast to other inherited metabolic disorders such as GD3 –there 
is no evidence of an impairment of the vestibular system in patients with NP-C, neither for canal 
nor for otolith function. Postural imbalance in these subjects is therefore mainly due to cerebellar 
dysfunction, which is supported by frequency analyses of posturographic data from these 
patients.  
In a cross-sectional study on the ocular motor system in patients with NP-C using a mobile 
video-oculographic tool, we identified different types of impairments of eye movements. These 
findings are the basis for large international cohort studies of pediatric and adult patients with 
NP-C. In these studies, the impairments of eye movements are correlated with other scales and 
are used as biomarker for the progression of the disease and the effects of therapy 
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